Journal articles: 'P.M. Barber and Company'

1

N, Zulkifli, Ria Novianti, and Meyke Garzia. "The Role of Preschool in Using Gadgets for Digital Natives Generation." JPUD - Jurnal Pendidikan Usia Dini 15, no. 2 (November 30, 2021): 221–38. http://dx.doi.org/10.21009/jpud.152.02.

Full text

Abstract:

Digital natives’ generation is inseparable from gadgets, less socializing, lack of creativity and being an individualist. The digital native’s generation wants things that are instant and lack respect for the process. The preoccupation of children with gadgets makes children socially alienated or known as anti-social. Preschool play an important role in the development of the digital native’s generation and in the future can help children use gadgets with parents. As it is known, the digital native’s generation is a kindergarten child. This study aims to determine the role of preschools in helping the use of gadgets in the digital native generation. This study used a descriptive quantitative approach with simple random sampling technique was obtained 25 kindergarten principals in Pekanbaru City. Data was collected in the form of a questionnaire via google form. Data analysis uses percentages and is presented in the tabular form. The results of the study indicate that the role of preschools in the use of gadgets in digital native generation children in Pekanbaru City is included in the low category. Only a few preschools have organized parenting education for parents. There are almost no rules governing children's use of gadgets at home, and few preschools educate children on how to use gadgets properly. It is expected for teachers and preschools to add special programs in the curriculum to provide information about positive gadget use and parenting programs that discuss digital native generation and collaborate with parents to establish rules such as frequency, duration and content of children using gadgets. Keywords: Digital Native, Preschool, Gadgets References: Alia, T., & Irwansyah, I. (2018). Pendampingan orang tua pada anak usia dini dalam penggunaan teknologi digital [parent mentoring of young children in the use of digital technology]. Polyglot: Jurnal Ilmiah, 14(1), 65–78. Allen, K. A., Ryan, T., Gray, D. L., McInerney, D. M., & Waters, L. (2014). Social Media Use and Social Connectedness in Adolescents: The Positives and the Potential Pitfalls. The Australian Educational and Developmental Psychologist, 31(1), 18–31. https://doi.org/10.1017/edp.2014.2 Berlin, A., Törnkvist, L., & Barimani, M. (2016). Content and Presentation of Content in Parental Education Groups in Sweden. The Journal of Perinatal Education, 25(2), 87–96. https://doi.org/10.1891/1058-1243.25.2.87 Chapman, G., & Pellicane, A. (2014). Growing up social: Raising relational kids in a screen-driven world. Moody Publishers. Cho, K.-S., & Lee, J.-M. (2017). Influence of Smartphone Addiction Proneness of Young Children on Problematic Behaviors and Emotional Intelligence. Comput. Hum. Behav., 66(C), 303–311. https://doi.org/10.1016/j.chb.2016.09.063 Coie, J. D., & Dodge, K. A. (1988). Multiple sources of data on social behavior and social status in the school: A cross-age comparison. Child Development, 815–829. Crouch, A. (2017). Tech-Wise Family. Everyday Steps for Putting Technology in Its Proper Place. Baker Books. De Lima, L., & Castronuevo, E. (2016). Perception of parents on children’s use of gadgets. The Bedan Journal of Psychology, II, 26–34. Gani, S. A. (2017). Parenting Digital Natives: Cognitive, Emotional, and Social Developmental Challenges. Guralnick, M. J. (1999). Family and child influences on the peer‐related social competence of young children with developmental delays. Mental Retardation and Developmental Disabilities Research Reviews, 5(1), 21–29. Hosokawa, R., & Katsura, T. (2018). Association between mobile technology use and child adjustment in early elementary school age. PloS One, 13(7), e0199959. Jonathan, L. P., & Andrew, L. F. (2016). Depression in children and adolescents. University of Kansas, Clinical Child Psychology Program. Kabali, H. K., Irigoyen, M. M., Nunez-Davis, R., Budacki, J. G., Mohanty, S. H., Leister, K. P., & Bonner, R. L. (2015). Exposure and Use of Mobile Media Devices by Young Children. PEDIATRICS, 136(6), 1044–1050. https://doi.org/10.1542/peds.2015-2151 Kirschner, P. A., & De Bruyckere, P. (2017). The myths of the digital native and the multitasker. Teaching and Teacher Education, 67, 135–142. https://doi.org/10.1016/j.tate.2017.06.001 Kurniawan, A. R., Chan, F., Sargandi, M., Yolanda, S., Karomah, R., Setianingtyas, W., & Irani, S. (2019). Kebijakan Sekolah Dalam Penggunaan Gadget di Sekolah Dasar [School Policy on the Use of Gadgets in Elementary Schools]. Jurnal Tunas Pendidikan, 2(1), 72–81. Martin, D. J. (2001). Constructing Early Childhood Science. Delmar Thomson Learning, Inc,. Morrongiello, B. A., McArthur, B. A., Goodman, S., & Bell, M. M. (2015). Don’t touch the gadget because it’s hot! Mothers’ and children’s behavior in the presence of a contrived hazard at home: Implications for supervising children. Journal of Pediatric Psychology, 40 1, 85–95. Mueller, S., Remaud, H., & Chabin, Y. (2011). How strong and generalisable is the Generation Y effect? A cross‐cultural study for wine. International Journal of Wine Business Research, 23(2), 125–144. https://doi.org/10.1108/17511061111142990 NAEYC. (2012). Technology and interactive media as tools in early childhood programs serving children from birth through age 8. National Institute for Educational Policy Research. (2014). Zenkoku Gakuryoku Gakusyu Jyokyo Cyosa [Japanese]. Nielsen Company. (2009). Television, Internet, and mobile usage in the U.S.: A2/M2 Three Screen Report. Nielsen Company. Nielsen, M. (2012). Imitation, pretend play, and childhood: Essential elements in the evolution of human culture? Journal of Comparative Psychology, 126(2), 170–181. https://doi.org/10.1037/a0025168 Novianti, R., Febrialismanto, F., Puspitasari, E., & Hukmi, H. (2020). Meningkatkan pengetahuan orang tua dalam mendidik anak di era digital di Kecamatan Koto Gasib Kabupaten Siak Provinsi Riau [Increasing parental knowledge in educating children in the digital era in Koto Gasib Sub-district, Siak Regency, Riau Province]. Riau Journal of Empowerment, 3(3), 183–190. https://doi.org/10.31258/raje.3.3.183-190 Novianti, R., & Garzia, M. (2020). Penggunaan Gadget pada Anak; Tantangan Baru Orang Tua Milenial[Use of Gadgets in Children; Millennial Parents' New Challenge]. Jurnal Obsesi: Jurnal Pendidikan Anak Usia Dini, 4(2), 1000–1010. Pediatrics, A. A. O. (2016). American Academy of Paediatrics announces new recommendations for children’s media use. Advocacy & Policy. Radesky, J. S., & Christakis, D. A. (2016). Increased Screen Time: Implications for Early Childhood Development and Behaviour. Paediatric Clinics of North America, 63(5), 827–839. https://doi.org/10.1016/j.pcl.2016.06.006 Ransdell, S., Kent, B., Gaillard-Kenney, S., & Long, J. (2011). Digital immigrants fare better than digital natives due to social reliance: Digital immigrants and social reliance. British Journal of Educational Technology, 42(6), 931–938. https://doi.org/10.1111/j.1467-8535.2010.01137.x Rideout, V., &. Robb, M. B., & Robb, M. B. (2020). The commonsense census: Media use by kids aged zero to eight. Common Sense Media. Scott, F. L. (2021). Family mediation of preschool children’s digital media practices at home. Learning, Media, and Technology, 1–16. https://doi.org/10.1080/17439884.2021.1960859 Setianingsih, S. (2018). Dampak penggunaan gadget pada anak usia prasekolah dapat meningkatan resiko gangguan pemusatan perhatian dan hiperaktivitas [The impact of using gadgets on preschool-aged children can increase the risk of attention deficit disorder and hyperactivity]. Gaster, 16(2), 191–205. Sharkins, K. A., Newton, A. B., Albaiz, N. E. A., & Ernest, J. M. (2016). Preschool Children’s Exposure to Media, Technology, and Screen Time: Perspectives of Caregivers from Three Early Childcare Settings. Early Childhood Education Journal, 44(5), 437–444. https://doi.org/10.1007/s10643-015-0732-3 Sheedy, A. J., Brent, J., Dally, K., Ray, K., & Lane, A. E. (2021). Handwriting Readiness among Digital Native Kindergarten Students. Physical & Occupational Therapy In Pediatrics, 41(6), 655–669. https://doi.org/10.1080/01942638.2021.1912247 Steiner-Adair, C., & Barker, T. H. (2013). The Big Disconnect (1st ed.). Harper Collins. Strasburger, V. C., Jordan, A. B., & Donnerstein, E. (2010). Health effects of media on children and adolescents. Pediatrics, 125(4), 756–767. Sugiyono. (2017a). Statistika untuk Penelitian[Statistics for Research]. Alfabeta. Sugiyono, P. (2017b). Metode Penelitian Pendidikan: Pendekatan Kuantitatif, Kualitatif, R&D [Educational Research Methods: Quantitative, Qualitative, R&D Approach]. Cetakan Ke-25. Bandung: CV Alfabeta. Suhana, M. (2018). Influence of Gadget Usage on Children’s Social-Emotional Development. 169(Icece 2017), 224–227. https://doi.org/10.2991/icece-17.2018.58 Sylva, K. (1994). School Influences on Children’s Development. Journal of Child Psychology and Psychiatry, 35(1), 135–170. https://doi.org/10.1111/j.1469-7610.1994.tb01135.x Takeuchi, H., Taki, Y., Hashizume, H., Asano, K., Asano, M., Sassa, Y., Yokota, S., Kotozaki, Y., Nouchi, R., & Kawashima, R. (2016). Impact of videogame play on the brain’s microstructural properties: Cross-sectional and longitudinal analyses. Molecular Psychiatry, 21(12), 1781–1789. Test, J. E., Cunningham, D. D., & Lee, A. C. (2010). Talking With Young Children: How Teachers Encourage Learning. Dimensions of Early Childhood, 38(3), 3–14. Tootell, H., Freeman, M., & Freeman, A. (2014). Generation Alpha at the Intersection of Technology, Play and Motivation. 2014 47th Hawaii International Conference on System Sciences, 82–90. https://doi.org/10.1109/HICSS.2014.19 Twenge, J. M. (2017). IGen: Why today’s super-connected kids are growing up less rebellious, more tolerant, less happy—And completely unprepared for adulthood—And what that means for the rest of us. Simon and Schuster. UNESCO. (2014). Information and Communication Technology (ICT) In Education in Asia. Information Papers, 6(22), 6. UNICEF. (2017). UNICEF for Every Child. The State of The World’s Children 2017. Children in a Digital World. Valkenburg, P. M., Peter, J., & Schouten, A. P. (2006). Friend Networking Sites and Their Relationship to Adolescents’ Well-Being and Social Self-Esteem. CyberPsychology & Behavior, 9(5), 584–590. ht

APA, Harvard, Vancouver, ISO, and other styles

2

PEGUM, J. S. "Harold Wordsworth Barber. THE ALIBERT SOCIETY (PATRON DR P. W. M. COPEMAN) 19th SEPTEMBER, 1984." Clinical and Experimental Dermatology 12, no. 1 (January 1987): 26–28. http://dx.doi.org/10.1111/j.1365-2230.1987.tb01849.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hephzibah, Abel Zebada, Amelia Maximova Nababan, and Nedichya Correia Belo. "CASE STUDY: THE STRENGTH AND WEAKNESS OF CORPORATE MERGERS AND ACQUISITIONS." Problematika Hukum 10, no. 1 (April 30, 2024): 1. http://dx.doi.org/10.33021/ph.v10i1.5282.

Full text

Abstract:

This study examines the impact of mergers and acquisitions (M&A) on company performance in emerging markets, using Indonesia as a case study. By analyzing data from the Business Competition Supervisory Commission (KPPU), it observes a significant rise in M&A activity during the pandemic. Unlike previous research, this study evaluates both short- and long-term effects on company performance, emphasizing the role of managerial ability (MA) in M&A success. While M&A offers benefits like diversification and access to new markets, it also poses risks such as unclear goals and cultural disparities. Successful M&A transactions can create value for shareholders, but careful planning, due diligence, and integration are essential for maximizing benefits and minimizing risks.Keywords: Merger and acquisition, corporate, business competition, asset, financial transaction.

APA, Harvard, Vancouver, ISO, and other styles

4

Alexander, Aneke, and Orji Tony. "The Influence of Previous CSR Activities on Attitude Towards the Company." International Journal of Business and Management Research 11, no. 3 (December 20, 2023): 89–95. http://dx.doi.org/10.37391/ijbmr.110303.

Full text

Abstract:

This study examined the influence of previous corporate social responsibility activities on attitude towards the company. The study adopted an experimental method, with a 3x2 factorial design, in which the first treatment condition was grouped into three, which include; control, diversity group and eco-friendly group. Participants in the first treatment condition were given positive information about the company CSR. Furthermore, the second treatment condition was divided into two; non-diversity and non-eco-friendly groups, participants were given negative information about the company’s CSR. The result gotten from the experimental study, shows that prior positive knowledge about company’s CSR has a significant effect on the attitude towards the company {F(2, 299) = 6.27, p = .002}, compared to prior negative knowledge about company’s CSR {F(2, 299) = 0.13, p = .878}, which is not significant. Individually, the result analysis reveals that both diversity group (M = 5.37, SD = 1.00) , 95% C.l. = [ .5.17, 5.56] and the eco-friendly group (M = 5.32, SD = 90) , 95% C.l. = [ .5.15, 5.50] that received positive information about the company’s CSR are significant on attitude towards the company compared to non-diversity (M = 5.18, SD = .98), 95% C.l. = [ 5.02, 5.33] and non-eco-friendly group (M = 5.24, SD = .97), 95% C.l. = [ 5.08, 5.39], which are insignificant in influencing attitude towards the company. Therefore, companies should endeavour to prioritize their CSR activities in order to get positive reviews and actions from customers and potential clients.

APA, Harvard, Vancouver, ISO, and other styles

5

Humbley, John. "Görlach, M. (2003): English Words Abroad, Amsterdam/Philadelphia, John Benjamins Publishing Company, 188 p." Meta: Journal des traducteurs 51, no. 3 (2006): 587. http://dx.doi.org/10.7202/013562ar.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Febby and Sugi Suhartono. "DETERMINAN PEMILIHAN KANTOR AKUNTAN PUBLIK (KAP)." Jurnal Akuntansi 9, no. 2 (August 15, 2020): 1–16. http://dx.doi.org/10.46806/ja.v9i2.758.

Full text

Abstract:

Abstract In the process of maximizing the value of the company, a conflict of interest between the manager and the shareholders often arises, which is often called an agency problem. This happens because managers prioritize the opposite interests, ownership does not like the personal interests of managers because what managers do will add costs to the company so that it will cause a decrease in corporate profits. Therefore, companies need a corporate monitoring function through external auditors that are used by company managers to reduce agency problems that arise in the company and reduce fraud in the presentation of the company's financial statements. Therefore, this study discusses the factors that can influence the decisions of public accounting firms such as institutional share ownership, managerial stock ownership, largest shareholding, company size, independent commissioners and leverage. The sample in this study consisted of 135 manufacturing companies. Sampling was done by purposive sampling method. The analytical method used is logistic regression analysis using SPSS 20. The conclusion from the results of the analysis in this study is that the largest shareholding has a positive interest in the selection of a public accounting firm. Keywords: Selection of Public Accounting Firm, Independent Commissioner, Institutional Ownership, Managerial Ownership, Largest Share Ownership, Company Size, Leverage. References: Alfian, N., & Suryansyah, A. (2017). "Pengaruh Efektivitas Komite Audit, Ukuran Perusahaan dan Leverage terhadap Pemilihan Auditor Eksternal." Jurnal Akuntansi Dan Investasi, Vol. 2, No. 2, p. 82â€“93. Anggraeni, O. L., & Ghofar, A. (2013). "Pengaruh Struktur Kepemilikan Dan Mekanisme Tata Kelola Korporat Terhadap Pemilihan Auditor Eksternal Berkualitas." Arens, A., A., R., J. Elder dan M., S., B. (2014). "Auditing Dan Jasa Assurance", Alih bahasa oleh Heran Wibowo, Jakarta: Penerbit Erlangga Cholifah, A. (2011). "Pengaruh Mekanisme Corporate Governance Terhadap Pemilihan Auditor Eksternal." Jurnal ULTIMA Accounting, Vol. 3, No. 1, p. 46â€“65. Darmadi, S. (2012). "Ownership Concentration, Family Control, and Auditor Choice: Evidence from an Emerging Market." SSRN Electronic Journal, No. 2, p. 1â€“42. Dewi, C. I. R. S., & Ratnadi, N. M. D. (2014). "Faktor-Faktor Yang Mempengaruhi Pemilihan Kantor Akuntan Publik Pada Industri Manufaktur Di Bursa Efek Indonesia," E-Jurnal Akuntansi Univesitas Udayana Vol. 8.1, p. 187â€“199. Dewi, C. I. R. S., Surya, L. P. L. S., & Suindari, N. M. (2019). "Pengaruh Leverage Dan Kepemilikan Institusional Pada Pemilihan Jasa Audit Eksternal (Studi Pada Perusahaan Pertambangan yang Terdaftar di Bursa Efek Indonesia)" Vol. 18, No. 1, p. 26â€“32. Eisenhardt, K. M. (1989). "Agency Theoryâ€¯: An Assessment and Review," Vol. 14, No. 1, p. 57â€“74. Fitriyani, N. M. D., & Erawati, N. M. A. (2016). "Good Corporate Governance Dan Karakteristik Perusahaan Pada Pemilihan Auditor Eksternal." E-Jurnal Akuntansi, Vol. 15, No. 1, p. 229â€“256. Ghozali, imam. (2016). "Aplikasi Analisis Multivariete Dengan Program IBM SPSS 23" (Edisi 8). Semarang: Universitas Diponegoro. Habeahan, M. S., & Habibi Z, M. R. (2017). "Analisis Mekanisme Corporate Governance dan Tipe Kepemilikan Perusahaan Terhadap Pemilihan Auditor Eksternal." Jurnal Mediasi Unimed, Vol. 6, No. 2, p. 73-93 Jensen, M. C., & Meckling, W. H. (1976). "Theory of The Firm Manajerial Behaviour, Agency Cost and Ownership structure." Journal of Financial Economics, No. 3, p 305â€“360. Knechel, W. R., Niemi, L., & Sundgren, S. (2008). "Determinants of Auditor Choice: Evidence from a Small Client Market." International Journal of Auditing, Vol. 12, No. 1, p. 65â€“88. Lennox, C. (2005). "Management ownership and audit firm size." Contemporary Accounting Research, Vol. 22, No.1, p. 205â€“227. Maharani, D. (2012). "Analisis Mekanisme Corporate Governance Perusahaan Terhadap Pemilihan Auditor Eksternal", p. 1â€“34. Maharani, D. A., & Pinasti, M. (2018). "Corporate Governance dan Pemilihan Auditor." Vol. 20, No. 3. Markali, O. E., & Rudiawarni, F. A. (2012). "Hubungan Mekanisme Corporate Governance dengan Pemilihan Auditor pada Badan Usaha", Vol. 1, No. 1, p. 1â€“17. Murhadi, W. R. (2009). "Good Corporate Governance and Earning Management Practices: An Indonesian Cases". Nafasati P, F., & Indudewi, D. (2015). "Pengaruh Mekanisme Internal Corporate Governance Terhadap Pemilihan Auditor Eksternal." Jurnal Dinamika Sosial Budaya, Vol. 17, No. 1. Putra, D. (2014). "Pengaruh Mekanisme Corporate Governance Terhadap Pemilihan Auditor Eksternal." Proseding Seminar Bisnis dan Teknologi. p. 148â€“159. Republik Indonesia (2008). Peraturan Menteri Keuangan, (2008) "Nomor: 17/PMK.01/2008 Tentang Jasa Akuntan Publik" Rosita, L., Respati, N. W., & Sondakh, A. G. (2015). "Pengaruh Kepemilikan Asing , Komisaris Independen, Efektivitas Komite Audit, Ukuran Perusahaan dan Leveragge Terhadap Pemilihan Auditor Eksternal." Simposium Nasional Akuntansi Vol. XX, No. 2, p. 1â€“18. Setiawan, A. S., & Karsana, Y. W. (2015). "Faktor Representasi Stock Holder dan Debt Holder Berpengaruh terhadap Keputusan Pemilihan Auditor Berkualitas." Jurnal Akuntansi, Vol. XIX, No. 03, p. 326â€“339. Trisnawati, I. T. A. (2015). "Faktor Determinan Pemilihan Auditor Eksternal Yang Berkualitas." Jurnal Bisnis Dan Akuntansi, Vol. 17, No. 2, p. 112â€“124. Zureigat, Q. M. (2011). "The Effect of Ownership Structure on Audit Quality: Evidence from Jordan." International Journal of Business and Social Science, Vol. 2, No. 10, p. 38â€“46.

APA, Harvard, Vancouver, ISO, and other styles

7

El Khaldi, Mohamed, Omar Laraqui, Nadia Manar, Frédéric Deschamps, and Chakib El Houssine Laraqui Hossini. "P-391 EVALUATION OF THE VIBRATIONAL ENVIRONMENTS OF THE HAND-ARM SYSTEM IN A WORKER ASSEMBLING METAL STRUCTURES." Occupational Medicine 74, Supplement_1 (July 1, 2024): 0. http://dx.doi.org/10.1093/occmed/kqae023.1059.

Full text

Abstract:

Abstract Introduction Musculoskeletal disorders are widely found among workers exposed to vibrations. The objective of our study is to identify and measure the vibrations of the hand-arm system encountered during the assembly of metal structures among a worker in an industrial company in Morocco as well as to evaluate their possible harmful effects on health. Method This metrological study was measuring the vibrations of the hand-arm system in a male worker who manipulates a drill and a bolter for the assembly of metal structures serving as support for the storage of pallets within an industrial company in Morocco. The study was using a hand-arm system sensor connected to an analyzer respectively when handling the two machines. Results When handling the wrench, the weighted equivalent acceleration Ahv was of the order of 3.39 m/s² while the daily exposure level Ahv(8) was 0.91 m/s². When handling the perforator, the weighted equivalent acceleration Ahv was of the order of 9.35 m/s² while the daily exposure level Ahv (8) was 3.81 m/s². The daily exposure level relative to the sum of the two Ahvt devices was 3.91 m/s². Discussion and conclusion The exposure level observed with the perforator exceeds the permitted values requiring a reduction in handling time. Corrective technical and organizational measures must be immediately put in place to prevent the occurrence of harmful effects of vibrations on health. The role of the occupational physician and the multidisciplinary team is of great importance in carrying out preventive actions.

APA, Harvard, Vancouver, ISO, and other styles

8

Visscher, Irene, and Roos Beerkens. "Organizational Identification at a Multinational Company." Journal of Intercultural Management 12, no. 3 (September 1, 2020): 67–98. http://dx.doi.org/10.2478/joim-2020-0045.

Full text

Abstract:

AbstractObjective: The present case study investigates to what extent employees working at the Dutch site of an American multinational biotechnology organization identify with this company. According to prior research, organizational identification leads to higher commitment to the organization. Gaining more insight into which factors drive or impede organizational identification can help organizations increase their employees’ identification and thus, commitment. Two hypotheses were tested. First, organizational identification was expected to be higher among international employees than Dutch employees. Second, a correlation was expected between organizational identification and organizational commitment.Methodology: A questionnaire was conducted among 296 employees of the company site. The scale of Edwards and Peccei (2007) was used to measure the construct of organizational identification. Mowday et al.’s (1979) Organizational Commitment Questionnaire was used to measure the construct of organizational commitment. All data was statistically analyzed with the software SPSS; an independent samples t-test was performed to test the first hypothesis and a Pearson correlation coefficient was computed to test the second hypothesis.Findings: Both hypotheses were confirmed. A significant difference was found between international employees (M = 5.25, SD = 1.05, n = 81) and Dutch employees (M = 4.96, SD = 1.12, n = 215) regarding organizational identification (t(293) = -2.03, p =.04, d = 0.27). Moreover, a significant positive correlation exists between organizational identification and organizational commitment (r(295) = .81, p < .001).Value Added: Most prior research regarding organizational identification has focused on top-down processes, stressing the roles managers play in developing organizational identification among employees. Scholars have devoted little attention to what factors drive or impede organizational identification in cross-cultural workplaces. Taking on a bottom-up perspective, this study concentrates on the impact of employees’ social identities, mainly considering expatriate membership, on the extent of their organizational identification.Recommendations: In order to increase organizational identification, multinational organizations could: 1) facilitate identity synergy by acknowledging the full portfolio of identities employees seek to enact within organizations, and 2) increase peer identification among employees by initiating group activities that facilitate peer-to-peer interactions, create a sense of community and strongly bond individuals to the organization.

APA, Harvard, Vancouver, ISO, and other styles

9

El Hadri, Mohamed, Omar Laraqui, Nadia Manar, Frédéric Deschamps, and Chakib El Houssine Laraqui Hossini. "P-389 EVALUATION OF THE VIBRATIONAL ENVIRONMENTS OF THE WHOLE-BODY SYSTEM IN A FORKLIFT DRIVER WITHIN AN INDUSTRIAL COMPANY." Occupational Medicine 74, Supplement_1 (July 1, 2024): 0. http://dx.doi.org/10.1093/occmed/kqae023.1057.

Full text

Abstract:

Abstract Introduction Vibrations constitute risk factors par excellence for musculoskeletal disorders (MSD), particularly at the spinal level for vibrations of the whole-body system. The objective of our study is to identify and measure whole-body system vibrations encountered when operating forklifts as well as to evaluate their possible association with health effects. Methods This is a metrological study for the measurement of whole-body system vibrations in a male forklift driver in an industrial company carried out in 2018 using two sensors, one for the seat and another for the floor, both connected to an analyzer. Results The duration of the measurement was 01h50min. The effective weighted accelerations obtained over the entire recorded activity were for the three axes X (anteroposterior): 0.25 m/s², Y (lateral): 0.23 m/s², Z (vertical) seat: 0.71 m/s² and Z (vertical) of the floor: 0.73 m/s. The weighted equivalent acceleration was Aeq: 0.71 m/s². The daily exposure value was Aeq(8): 0.65 m/s². Discussion The exposure values found exceed the values triggering preventive action but still remain lower than the values prohibiting work. Conclusion Corrective organizational and preventive medical measures must be put in place to prevent the occurrence of the harmful effects of vibrations on the health of workers.

APA, Harvard, Vancouver, ISO, and other styles

10

Gale, Andrew, Peter Bengtson, and William James Kennedy. "Ammonites at the Cenomanian–Turonian boundary in the Sergipe Basin, Brazil." Bulletin of the Geological Society of Denmark 52 (December 31, 2005): 167–91. http://dx.doi.org/10.37570/bgsd-2005-52-13.

Full text

Abstract:

Two distinctive ammonite faunas are described from the Cenomanian–Turonian boundary interval in the Sergipe Basin, Brazil. The Jardim 1 section assemblage comprises Euomphaloceras costatum Cobban, Hook & Kennedy, 1989, Burroceras transitorium Cobban, Hook & Kennedy, 1989, Pseudaspidoceras pseudonodosoides Choffat, 1898, and Vascoceras cf. gamai Choffat, 1898. This same association is found in New Mexico, where it occurs with the upper Cenomanian index fossil Neocardioceras juddii (Barrois & Guerne, 1898). On this basis the Sergipe assemblage is referred to the N. juddii Zone, and correlated with beds 79–84 of the Pueblo, Colorado section. These lie 1.14–0.63 m below the Global boundary Stratotype Section and Point (GSSP) for the base of the Turonian Stage, the base of bed 86, which corresponds to the first occurrence of the ammonite Watinoceras devonense Wright & Kennedy, 1981. The Japaratuba 16 locality in Sergipe yielded an assemblage of Pachydesmoceras kossmati Matsumoto, 1987, Watinoceras coloradoense (Henderson, 1908), Pseudaspidoceras flexuosum Powell, 1963, Pseudovascoceras nigeriense (Woods, 1911), Vascoceras globosum globosum (Reyment, 1954), V. simplex (Barber, 1957), and Pseudotissotia nigeriensis (Woods, 1911). The co-occurrence of W. coloradoense and P. flexuosum is also found in the Pueblo section, in bed 97, 1.65 m above the base of the Turonian. These ammonite records thus allow the placement of the Cenomanian–Turonian boundary in the Sergipe-Alagoas Basin, and correlation with the Global Boundary Stratotype Section and Point at Pueblo.

APA, Harvard, Vancouver, ISO, and other styles

11

Pavio, Nicole, Deborah R. Taylor, and Michael M. C. Lai. "Detection of a Novel Unglycosylated Form of Hepatitis C Virus E2 Envelope Protein That Is Located in the Cytosol and Interacts with PKR." Journal of Virology 76, no. 3 (February 1, 2002): 1265–72. http://dx.doi.org/10.1128/jvi.76.3.1265-1272.2002.

Full text

Abstract:

ABSTRACT The hepatitis C virus (HCV) envelope protein E2 has been shown to accumulate in the lumen of the endoplasmic reticulum (ER) as a properly folded glycoprotein as well as large aggregates of misfolded proteins. In the present study, we have identified an additional unglycosylated species, with an apparent molecular mass of 38 kDa (E2-p38). In contrast to the glycosylated E2, E2-p38 is significantly less stable and is degraded through the proteasome pathway. Correspondingly, E2-p38 is found to be ubiquitinated. E2-p38 is localized mostly in the cytosol, in contrast to the glycosylated form, which is exclusively membrane associated. Alpha interferon (IFN-α) treatment or overexpression of the double-stranded RNA-activated protein kinase (PKR) significantly increased the stability of E2-p38, consistent with a previous report (D. R. Taylor, S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai, Science 285:107–110, 1999) that E2 interacts with PKR and inhibits its kinase activity. Direct interaction between PKR and E2-p38, but not the glycosylated form of E2, was also observed. These results show that E2-p38 is the form of E2 that interacts with PKR in the cytosol and may contribute to the resistance of HCV to IFN-α. Thus, an ER protein can exist in the cytosol as an unglycosylated species and impair cellular functions.

APA, Harvard, Vancouver, ISO, and other styles

12

Fitri, Idul, Khairani Khairani, and Yasniwati Yasniwati. "Perlindungan Hukum terhadap Pekerja Alih Daya dalam Perjanjian Kerja dalam Hal Terjadi Peralihan Perusahaan Penyedia Jasa." Nagari Law Review 7, no. 3 (June 30, 2024): 660. http://dx.doi.org/10.25077/nalrev.v.7.i.3.p.660-671.2024.

Full text

Abstract:

Outsourced labor is a part of employment growth in various economic sectors. As part of the workforce, outsourcing workers must also receive protection for their rights as outsourcing workers. One of the things that needs to be protected is in the event of a transfer of service provider company. Therefore, it is necessary to study the protection of the rights of outsourced workers. In this case, the research was conducted at the M. Zein Painan Hospital. Outsourced workers at M. Zein Painan Hospital must be protected by Indonesian law. The study used empirical research methods by collecting data from related parties, namely outsourcing workers, service provider companies, and service users, in this case, Dr. M Zein Painan. One form of legal protection and certainty, especially for workers, is through the implementation of work agreements. Analysis and discussion of the results obtained are: (a) Forms of legal protection for outsourced workers in work agreements at RSUDi Dr. M. Zein Painan, namely protection of wages, protection of working time, and protection of rest time as well as protection against termination of employment (b) Implementation of work agreements for outsourced workers when there is a change in service provider company can be implemented well with the existence of an agreement Work.

APA, Harvard, Vancouver, ISO, and other styles

13

Shumilova, Viktoriia. "The Virsky Ukrainian National Dance Company in the scope of the art research (between 2010–2020 years)." National Academy of Managerial Staff of Culture and Arts Herald, no. 2 (September 17, 2021): 211–16. http://dx.doi.org/10.32461/2226-3209.2.2021.240067.

Full text

Abstract:

The purpose of the article has been to learn new historical, cultural and art sources have been posted between 2010–2020 years, related to the Virsky Ukrainian National Dance Company occupation that. The methodology includes the researching methods usage such as: overall historical, comparative-historical, dialectical, analytical, systemic, etc. The scientific novelty implies the novice in the researched historiographical sources made up between 2010–2020 years that have significantly boosted the scientific projection to learn the historical and art facts related to the Virsky Ukrainian National Dance Company occupation. Conclusions. The historical timeline between 2010–2020 years related to the Virsky Ukrainian National Dance Company art outcomes is presented by modern domestic researcher’s monographs and publications such as: T. Blagova, O. Burkovsky, N. Vadiasova, D. Vernygor, Y. Vernygor, E. Dosenko, M. Kurinna, V. Lytvynenko, E. Roy, R. Savchenko, N. Semenova, V. Chernets, V. Shulgina, V. Shumilova etc. Due to inquire the life and creative path the choreographers who have served for the USSR State Dance Ensemble (P. Virsky, M. Vantukh), the researchers analyzed the main phases to come up with their art approaches, determined to search the chiefs regarding to the extraordinary compositional consistency, observed the dynamic to develop the musical-choreographic drama by the Virsky Ukrainian National Dance Company modern dance performances etc.

APA, Harvard, Vancouver, ISO, and other styles

14

Mendiola, Vincent Louie Ramos, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, et al. "Superior Outcomes in Hispanic Patients Compared to Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen for Newly Diagnosed ALL Patients in the Era of Novel Agents; A Retrospective Study." Blood 138, Supplement 1 (November 5, 2021): 3361. http://dx.doi.org/10.1182/blood-2021-150116.

Full text

Abstract:

Abstract INTRODUCTION: Hispanic patients with acute lymphoblastic leukemia (ALL) are historically known to have poor outcomes compared to non-Hispanic patients. Our institution, LAC-USC (LA County Hospital/University of Southern California) has shown a complete remission rate of 96% with use of pegasparagase at 2000 IU/m2 using the USC ALL regimen (based on CCG-1882) for patients aged 17-55 years with a 7-year OS of 51% reported in 2014. The modified USC ALL regimen now uses a single dose of cytarabine rather than fractionated doses and uses a single dose 3g/m 2 methotrexate compared to 1g/m 2 (2.5g/m 2 if T-cell) D1, 15 in original USC ALL regimen to improve compliance, while consolidation was increased to six cycles allowing for PEG holidays to improve toxicity (Table 1). Since our institution takes care of a large population of Hispanic patients with ALL, we now report outcomes in Hispanic and Non-Hispanic patients using the modified USC ALL regimen in the era of novel agents like blinatumomab and inotuzumab. METHODS : This retrospective, single institution chart review included adults >18 years old with newly diagnosed Ph-negative ALL (2016-2020). Primary objectives were 3-year over-all survival (OS), event-free survival (EFS), disease-free survival (DFS). Secondary objectives were complete remission/complete remission with incomplete recovery (CR/CRi), minimal residual disease (MRD) by flow cytometry, descriptive statistics of patients who were stratified into Hispanic and non-Hispanic cohorts and evaluated using Fisher's exact test. OS, DFS, EFS were reported through Kaplan Meier curves and Log-rank tests. Two-sided p-value ≤0.05 was significant. RESULTS: 121 Ph-negative patients were reviewed. 87 were Hispanic patients (HP) and 34 non Hispanic patients (NHP). Median ages were 39 and 35 years (p=0.51) and median BMI were 29 and 26.9 kg/m 2 (p=0.42), respectively. There were about equal males and females in HP while NHP had 70.6% males compared to 29.4% females (p=0.076). Both HP and NHP were mainly of the Ph-negative ALL subtype, 50.6% vs 47.1%, followed by Ph-like, 25.4% vs 20.6%, respectively (p=0.884). Majority of the population were unfavorable risk by NCCN karyotypic risk stratification, 55.9% in HP compared to 56.0% in NHP (p=0.99). Over-all, no significant difference between baseline characteristics in both cohorts. After induction 1: CR/CRi was 85.9% in HP and 73.4% in NHP (p=0.09). MRD negativity by flow cytometry in HP was 41.4% compared to 26.4% in NHP (p=0.13). After induction 2: 83% of HP were in CR/CRi compared to 80% in NHP (p=0.99) and MRD negativity by flow was 35.6% in HP compared to 32.4% in NHP (p=0.73). Blinatumomab was given in 33.3% of HP and 32.3% of NHP (p=0.92) while only 5.7% of HP and 2.9% of NHP received inotuzumab (p=0.99). 34.5% of HP underwent allogenic hematopoietic stem cell transplant (allo-HSCT) versus 26.5% in NHP (p=0.40). 3-year OS was 92.2% in HP versus 67.4% in NHP (p=0.004). 3-year DFS was 92.8% in HP versus 60.7% in NHP (p=0.003). 3-year EFS was 54.1% in HP versus 32.3% in NHP (p=0.02) (Table 2). Rate of relapse for HP and NHP were 23.4% vs 29.4% (p=0.74) while rate of mortality for HP and NHP were 7.5% vs 28% (p=0.015), respectively. No clear difference in grade 3/4 PEG toxicities were found in HP and NHP except more hypertriglyceridemia in HP (p=0.019). CONCLUSIONS: We present comparison of outcomes in Hispanic and non-Hispanic patients using our modified USC ALL pediatric-based regimen in an era of novel agents. Our data shows significantly better outcomes in Hispanic patients compared to non-Hispanic patients [OS (92.2% vs 67.4%, p=0.004), DFS (92.8% vs 60.7%, p=0.003) and EFS (54.1% vs 32.3%, p=0.02)]. This study demonstrates that given equal access to care (eg. receiving blinatumomab, allo-HSCT), outcomes in HP with Ph-negative ALL are not worse, but rather superior to those in NHP. Utilization of novel immunotherapy like blinatumomab in the salvage setting to achieve deeper molecular response and increased utilization of haploidentical allo-HSCT have likely contributed to reducing ethnic disparities in Hispanic ALL patients. Future studies are needed to validate these findings with larger patient populations. Figure 1 Figure 1. Disclosures Chaudhary: Oncotartis: Consultancy; Pancella: Consultancy; Moderna: Current equity holder in publicly-traded company; Celldex: Current equity holder in publicly-traded company; TCR2: Current equity holder in publicly-traded company; Allogene: Current equity holder in publicly-traded company; Athelas: Consultancy, Current holder of stock options in a privately-held company; Angeles Therapeutics: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: Founder, Patents & Royalties: Cell therapy . Douer: Jazz: Consultancy; Amgen: Consultancy, Speakers Bureau; Adaptive: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Speakers Bureau; Servier: Consultancy, Speakers Bureau. Yaghmour: Takeda: Consultancy, Speakers Bureau; Astellas: Speakers Bureau; Alexion: Speakers Bureau; BMS: Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Jazz: Speakers Bureau.

APA, Harvard, Vancouver, ISO, and other styles

15

Platt, Jason, John S. Caldwell, and L. T. Kok. "Effect of Buckwheat as a Flowering Border on Populations of Cucumber Beetles and Their Natural Enemies in Cucumber and Squash." HortScience 32, no. 3 (June 1997): 511C—511. http://dx.doi.org/10.21273/hortsci.32.3.511c.

Full text

Abstract:

Cucumber beetles Acalymma vittatum (Fab.) and Diabrotica undecimpunctata howardi (Barber) (Coleoptera: Chrysomelidae) are major pests of cucurbits, and biological methods are needed for their control. A floral border of buckwheat Fagopyrum esculentum (Moench) was planted perpendicular to Cucumis sativa L. `Arkansas Littleleaf' and Cucurbita pepo L. `Seneca' rows to assess effects on populations of cucumber beetles and the presence of natural enemies. Numbers of Diptera were used as an indicator of potential border attractiveness to natural enemies Celatoria diabroticae (Shimer) and Celatoria setosa (Coquillett) (Diptera: Tachinidae). Sticky traps and modified Malaise traps at increments from the border were used to monitor insect numbers. There was a quadratic decline from 19.5 Diptera in the border to 2.8 Diptera at 20 m from the border in June 1995 and linear declines from 14.8 and 14.2 Diptera in the border to 9.8 and 6.8 Diptera at 36 m in June and Aug. 1996, respectively. Numbers of striped cucumber beetles were variable, with a non-significant (P = 0.08) linear increase from 13.0 insects in the border to 17.5 insects at 36 m in June 1995, but quadratic decreases to 27 m in June, July, and Sept. 1996. Similar declines as distance from the border increased were found in numbers of tachinid flies (Diptera: Tachinidae) and Hymenoptera wasps and Pennsylvania leatherwings, Chauliognathus pennsylvanicus (Deg.) (Coleoptera: Cantharidae) and lady beetles (Coleoptera: Coccinellidae) in 1996. No meaningful effects on cucumber (1995) or squash (1995 and 1996) yield were found. Although the natural populations of Celatoria spp. were not high enough to achieve control, these results suggest that flowering borders may be useful as habitats for releasing natural enemies of cucumber beetles. Numbers of Pennsylvania leatherwings, Chauliognathus pennsylvanicus (Deg.) (Coleoptera: Cantharidae) showed a significant linear decline from 2.1 insects in the border to 0.2 insects at 36 m in June 1996, but no significant relationship was found in 1995 or in Aug. 1996.

APA, Harvard, Vancouver, ISO, and other styles

16

Danese, S., A. Dignass, K. Matsuoka, M. Ferrante, M. Long, I. Redondo, T. H. Gibble, et al. "A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (March 1, 2023): 28–29. http://dx.doi.org/10.1093/jcag/gwac036.184.

Full text

Abstract:

Abstract Background Mirikizumab (miri), an anti-IL23/p19 monoclonal antibody, demonstrated efficacy compared with placebo (PBO) in the Phase 3, multicentre, randomized, double-blind LUCENT-1 induction study in patients with moderately to severely active ulcerative colitis (UC, NCT03518086). Purpose This analysis assessed early onset of symptomatic improvement and symptomatic control during induction. Method During the 12-week (W) induction study, 1162 adult patients (pts) with inadequate response, loss of response, or were intolerant to conventional therapy or biologic or tofacitinib therapy for UC, received miri IV Q4W (N=868) or PBO (N=294). We evaluated improvement for symptoms of stool frequency (SF), rectal bleeding (RB) and bowel movement urgency (BU), abdominal pain and fatigue. BU Numeric Rating Scale (NRS) change from baseline (BL), BU Clinical Meaningful Improvement (CMI), BU Remission, Fatigue NRS change from BL, Abdominal Pain Improvement, as well as SF Remission, RB Remission, Symptomatic Response and Symptomatic Remission were assessed. Result(s) As early as W2, miri-treated pts achieved a significantly greater reduction in RB subscores (p=0.001) and in SF subscores (p=0.035). From W2 and W4, a significantly greater percentage achieved SF Remission and RB Remission, respectively compared to PBO. A significantly greater percentage of miri-treated pts achieved Symptomatic Response compared to PBO from W2 (p=0.003) and of Symptomatic Remission compared with PBO from W4 (p<0.001). Miri-treated pts showed a significantly greater mean reduction in BU NRS scores as early as W2 compared to PBO (p=0.004). From W4, a significantly greater percentage of miri-treated pts achieved BU CMI versus PBO (p=0.044). From W7 onwards, a significantly greater percentage achieved BU Remission (p=0.002). The pts showed a significantly greater mean reduction in Fatigue NRS scores from W2 compared to PBO (p=0.014). As early as W4, a significant reduction of at least 30% in Abdominal Pain NRS score from BL was observed in the miri-treated pts compared with PBO (p=0.007). At W12, a significantly greater proportion of miri-treated pts achieved Symptomatic Response, Symptomatic Remission, RB Remission, SF Remission, BU change from BL, BU CMI and Remission, as well as Fatigue and Abdominal Pain Improvement, compared to PBO (Table). Image Conclusion(s) Miri provides rapid control of UC symptoms, including BU and fatigue, as early as W2 compared with PBO in pts with moderately to severely active UC. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Eli Lilly and Company Disclosure of Interest S. Danese Consultant of: AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Mundipharma, Mylan, Pfizer, Roche, Sandoz Sublimity, Takeda, TiGenix, UCB Pharma, and Vifor Pharma, Speakers bureau of: AbbVie, Amgen, Ferring Pharmaceuticals, Gilead Sciences, Janssen, Mylan, Pfizer, and Takeda, A. Dignass Consultant of: AbbVie, Abivax, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb (Celgene), Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Pharmacosmos, Roche, Sandoz/Hexal, Takeda, Tillotts Pharma AG, and Vifor Pharma, Speakers bureau of: AbbVie, Amgen, Bristol Myers Squibb, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos, High5Md, Janssen, Materia, Merck Sharp & Dohme, Pfizer, Sandoz, Takeda, Tillotts Pharma AG, and Vifor Pharma, K. Matsuoka Grant / Research support from: AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Kyowa Kyorin, Mitsubishi Tanabe, Mochida Pharmaceutical, and Zeria Pharmaceutical Nippon, Speakers bureau of: AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Kyowa Kyorin, Mitsubishi Tanabe, Mochida Pharmaceutical, Takeda, and Zeria Pharmaceutical Nippon, M. Ferrante Grant / Research support from: AbbVie, Amgen, Biogen, Janssen Cilag, Pfizer, Takeda, and Viatris, Consultant of: AbbVie, Boehringer Ingelheim, Celltrion, Eli Lilly and Company, Janssen Cilag, Medtronic, Merck Sharp & Dohme, Pfizer, Regeneron, Sandoz, Takeda, and Thermo Fisher Scientific, Speakers bureau of: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Janssen, Lamepro, Medtronic, Merck Sharp & Dohme, Mylan, Pfizer, Samsung Bioepis, Sandoz, Takeda, and Thermo Fisher Scientific, M. Long Consultant of: AbbVie, Bristol Myers Squibb, Calibr, Eli Lilly and Company, Genentech, Janssen, Pfizer, Prometheus Biosciences, Roche, Takeda, TARGET PharmaSolutions, and Theravance Biopharma, I. Redondo Employee of: Eli Lilly and Company, T. Gibble Employee of: Eli Lilly and Company, R. Moses Employee of: Eli Lilly and Company, N. Morris Employee of: Eli Lilly and Company, X. Li Employee of: Eli Lilly and Company, C. Milch Employee of: former employee, was employed at Eli Lilly and Company at the time of study, M. Abreu Grant / Research support from: Pfizer, Prometheus Biosciences, and Takeda, Consultant of: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Janssen, Microba Life Sciences, Prometheus Biosciences, UCB Pharma, and WebMD, Speakers bureau of: Alimentiv, Intellisphere LLC (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda, J. Jones: None Declared

APA, Harvard, Vancouver, ISO, and other styles

17

Purwanto, Agus Sulih, and Ruslan Prijadi. "The Role of Entrepreneurial Leadership to Maintain Company Performance Post Mergers & Acquisition." Al Qalam: Jurnal Ilmiah Keagamaan dan Kemasyarakatan 18, no. 3 (April 2, 2024): 1656. http://dx.doi.org/10.35931/aq.v18i3.3179.

Full text

Abstract:

Mergers and acquisitions (M&A deals) are one of the most important events in a company's life cycle and have a significant impact on a company's operations and activities. There are 3 objectives of this research, namely (1) Investigating factors (criteria) of acquiring companies and target companies in the Merger and Acquisition process (2) Investigating leadership characteristics in post-merger and acquisition companies (3) Investigating the role of leadership in achieving company performance that has been achieved. completing the merger and acquisition process in the insurance industry. Researchers used a qualitative approach with a case study method. Based on the level of crystallization of the research question, this research is an exploratory study. This research uses interviews as a primary data source obtained from sources. Qualitative data analysis in this research uses a thematic analysis approach, which is the basic method for conducting qualitative analysis with the help of NVIVO software. Based on the results of research and discussions that have been carried out, the conclusions that can be drawn are (1) factors (criteria) for acquiring companies and target companies in the merger and acquisition process, each of which has its own specificity (2) leadership roles in post-merger and acquisition companies to achieve organizational performance and growth of experience, vision and knowledge; decision making skills; communication skills; team building skills and skills in managing change (3) Key variables for the performance of companies that have completed the merger and acquisition process in the insurance industry are the scope of the merger and acquisition process, the methods used to complete the M&A process and the impact of M&A on performance , employees, work partners and customers.

APA, Harvard, Vancouver, ISO, and other styles

18

Costello, Caitlin, Ben A. Derman, Mehmet Hakan Kocoglu, Abhinav Deol, Abbas Abbas Ali, Tara Gregory, Bhagirathbhai Dholaria, et al. "Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System." Blood 138, Supplement 1 (November 5, 2021): 3858. http://dx.doi.org/10.1182/blood-2021-151672.

Full text

Abstract:

Abstract P-BCMA-101 and P-BCMA-ALLO1, autologous and allogeneic BCMA targeting CAR-T cell therapies respectively, are manufactured using a novel transposon-based system called piggyBac (PB). They comprise a high percentage of desirable stem cell memory T-cells associated with efficacy and safety. Single agent P-BCMA-101 data was previously reported showing marked efficacy and minimal toxicity (PRIME study), and exploratory combination cohorts have also been evaluated. P-BCMA-ALLO1 is expected to be first assessed in patients by the time of this presentation. Here we report results for P-BCMA-101 exploratory cohorts and P-BCMA-ALLO1. PRIME is a Phase 1/2 clinical trial to assess the safety and efficacy of P-BCMA-101 in patients with RRMM (≥ 3 prior lines, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or double refractory) (NCT03288493). Patients undergo apheresis to harvest T cells and P-BCMA-101 is then manufactured. Patients then receive a 3-day cyclophosphamide (300 mg/m 2/day) / fludarabine (30 mg/m 2/day) lymphodepletion (LDC) regimen. Following 2 days of rest, patients received a single administration of P-BCMA-101 in escalating doses starting at 0.75 x 10 6 CAR-T cells/kg. Similar P-BCMA-101 dose escalation was performed in combination cohorts with rituximab (Rit) or lenalidomide (Len). During the study, use of a nanoplasmid (NP) vector in CAR-T manufacturing was implemented to improve transposition efficiency and cell quality. As of June 30 th, 2021, 90 unique patients have been treated with P-BCMA-101 in 5 dose levels of single agent P-BCMA-101, 3 dose levels of P-BCMA-101 with Rit and 2 dose levels of P-BCMA-101 with Len. The median age is 61 years and 66/37% were M/F. Patients were heavily pre-treated with a median of 6 prior regimens (range 3-18), 100% had received prior PI and IMiD, 74% daratumumab and 63% ASCT. 13 patients were treated in combination with Rit and 9 in combination with Len. Like prior reports of P-BCMA-101, the safety profile compares favorably to other CAR-T. No dose limiting toxicities (DLT) were observed in the single agent or the combination cohorts. The addition of Rit or Len did not increase toxicity. Grade 1-2 CRS was seen in 25% (no G3/4) of patients and ICANS in 7% (2% G3). Tocilizumab was used in 11% of patients. There were no treatment related deaths or unexpected/off-target toxicities. The most common treatment emergent adverse events were cytopenias, infections and constitutional symptoms (≥ G3 neutropenia 74%, thrombocytopenia 30%, anemia 35%), as expected with CAR-T and LDC. The overall response rate (ORR) with the Rit and Len combinations was 73% and 71% respectively. The favorable safety profile allowed outpatient treatment in 23 (25%) patients. Founded on the P-BCMA-101 data, an allogeneic CAR-T (P-BCMA-ALLO1) using a similar PB construct was created and demonstrated excellent preclinical safety and efficacy leading to the initiation of a Phase 1 clinical trial (NCT04960579). P-BCMA-ALLO1 CAR-T cells are generated from healthy donor T-cells using Cas-CLOVER to knockout Beta-2 microglobulin to prevent host vs graft rejection, TCRβchain for graft vs host disease prevention. Proprietary booster molecules are utilized to increase manufacturing yield and cell quality. The CAR binding domain is a novel anti-BCMA VCAR that produced superior efficacy in tumor models. These constructs contain the same PB transposon transgene cassette, DHFR for gene selection and an iCasp9-based safety switch, successfully assessed in the PRIME study. The primary objective of the P-BCMA-ALLO1 phase 1 trial is to assess the safety and maximum tolerated dose (MTD) based on DLT in RRMM patients who have received a PI, IMid and CD38 mAb. Secondary objectives will assess the anti-myeloma effect of P-BCMA-ALLO1 and biomarkers. The protocol is designed to treat 40 RRMM patients in a standard 3+3 dose escalation with a P-BCMA-ALLO1 starting dose of 0.75 X 10 6 cells/kg. Patients will receive P-BCMA-ALLO1 following LDC with cyclophosphamide (300 mg/m 2/day) / fludarabine (30 mg/m 2/day X 3 days. In conclusion, transposon generated autologous CAR-T cells demonstrate excellent clinical activity with a favorable toxicity profile in RRMM, can be safely combined with Len and Rit, and administered in the outpatient setting. Allogeneic CAR-T cells generated from this platform represent a further advance. Current data from both clinical studies will be presented. Disclosures Derman: Sanofi: Membership on an entity's Board of Directors or advisory committees. Deol: Kite, a Gilead Company: Consultancy. Ali: BMS: Research Funding; Aduro: Research Funding; Poseida: Research Funding; Aduro: Consultancy; Amgen: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; BMS: Consultancy; Janssen: Consultancy. Dholaria: Pfizer: Research Funding; MEI: Research Funding; Poseida: Research Funding; Takeda: Research Funding; Janssen: Research Funding; Angiocrine: Research Funding; Jazz: Speakers Bureau; Celgene: Speakers Bureau. Berdeja: Bioclinica: Consultancy; BMS: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Lilly: Research Funding; Abbvie: Research Funding; EMD Sorono: Research Funding; Takeda: Consultancy, Research Funding; Prothena: Consultancy; Servier: Consultancy; Janssen: Consultancy, Research Funding; Karyopharm: Consultancy; Vivolux: Research Funding; Cellularity: Research Funding; Novartis: Research Funding; Poseida: Research Funding; CURIS: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Acetylon: Research Funding; Amgen: Consultancy, Research Funding; Teva: Research Funding; Legend: Consultancy; Kite Pharma: Consultancy; Bluebird: Research Funding; Constellation: Research Funding; Glenmark: Research Funding; Genentech: Research Funding; Kesios: Research Funding. Cohen: GlaxoSmithKline: Consultancy, Research Funding; AstraZeneca: Consultancy; Genentech/Roche: Consultancy; BMS/Celgene: Consultancy; Novartis: Research Funding; Oncopeptides: Consultancy; Takeda: Consultancy; Janssen: Consultancy. Patel: Oncopeptides: Consultancy; BMS Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Pfizer: Consultancy. Siegel: Karyopharm: Honoraria; Amgen Inc.: Honoraria; Takeda: Honoraria; Bristol Myers Squibb: Honoraria, Speakers Bureau; GlaxoSmithKline: Honoraria, Speakers Bureau; Celularity: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Speakers Bureau. Nath: Actinium: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. McArthur: Poseida: Current Employment, Current equity holder in publicly-traded company. McCaigue: Poseida: Current Employment, Current equity holder in publicly-traded company. Martin: Poseida: Current Employment, Current equity holder in publicly-traded company. Ghoddusi: Poseida: Current Employment, Current equity holder in publicly-traded company. Namini: Poseida: Current Employment, Current equity holder in publicly-traded company. Ostertag: Poseida: Current Employment, Current equity holder in publicly-traded company. Spear: Poseida: Current Employment, Current equity holder in publicly-traded company. Belani: Poseida Therapeutics: Current Employment, Current equity holder in publicly-traded company; Amgen: Current equity holder in publicly-traded company. Shah: Indapta Therapeutics: Consultancy; CareDx: Consultancy; BMS/Celgene: Research Funding; Amgen: Consultancy; Janssen: Research Funding; Bluebird Bio: Research Funding; Precision Biosciences: Research Funding; Karyopharm: Consultancy; Nektar: Research Funding; Oncopeptides: Consultancy; Poseida: Research Funding; Sanofi: Consultancy; CSL Behring: Consultancy; Kite: Consultancy; GSK: Consultancy; Sutro Biopharma: Research Funding; Teneobio: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

19

Markowski, Krzysztof, and Piotr Miluski. "Analysis of amplified spontaneous emission in ring-core Tm3+-doped optical fiber." Photonics Letters of Poland 15, no. 4 (December 31, 2023): 78–80. http://dx.doi.org/10.4302/plp.v15i4.1252.

Full text

Abstract:

This paper presents the results of numerical simulations of a ring-core thulium-doped silica fiber (RC-TDF). Enhanced spontaneous emission (ASE) was generated for a fiber with 4wt.% thulium content. An analysis of the formation of the ASE spectrum parameters (λmax, FWHM, output power) as a function of fiber length is also shown. The modal map is presented as a combination of outer and inner core radii and ∆n. Full Text: PDF References Y. Huang, Q. Xu, S. Peng, C. Xu, T. Liao, "2 μm Laser generation and amplification based on dual Tm3+-doped high-Q silica microsphere using an ASE light source for pumping", Opt Laser Technol , 153, 108282 (2022). CrossRef D. Theisen-Kunde, V. Ott, R. Brinkmann, R. Keller, "Potential of a new cw 2 μm laser scalpel for laparoscopic surgery", Med Laser Appl. 22, 139 (2007). CrossRef N.P. Barnes, B.M. Walsh, D.J. Reichle, R.J. DeYoung, "Tm:fiber lasers for remote sensing", Opt Mater (Amst), 31, 1061 (2009). CrossRef S.W. Henderson, C.P. Hale, J.R. Magee, M.J. Kavaya, A.V. Huffaker, "Eye-safe coherent laser radar system at 2.1 μm using Tm,Ho:YAG lasers", Opt Lett, 16, 773 (1991). CrossRef S.D. Jackson, "Cross relaxation and energy transfer upconversion processes relevant to the functioning of 2 μm Tm3+-doped silica fibre lasers", Opt Commun. 230, 197 (2004). CrossRef J. Wu, S. Jiang, T. Luo, J. Geng, N. Peyghambarian, N.P. Barnes, "Efficient thulium-doped 2-μm germanate fiber laser", IEEE Phot Technol Lett. 18, 334 (2006). CrossRef M.J. Barber, P.C. Shardlow, P. Barua, J.K. Sahu, W.A. Clarkson, "Nested-ring doping for highly efficient 1907nm short-wavelength cladding-pumped thulium fiber lasers", Opt Lett. 45, 5542 (2020). CrossRef P. Miluski, K. Markowski, M. Kochanowicz, M. Łodziński, J. Żmojda, W.A. Pisarski, J. Pisarska, M. Kuwik, M. Leśniak, D. Dorosz, T. Ragiń, V. Askirka, J. Dorosz, "Tm3+/Ho3+ profiled co-doped core area optical fiber for emission in the range of 1.6–2.1 µm", Sci Rep. 13, 13963 (2023). CrossRef H. Ono, T. Hosokawa, K. Ichii, S. Matsuo, H. Nasu, M. Yamada, "2-LP mode few-mode fiber amplifier employing ring-core erbium-doped fiber", Opt Express, 23, 27405 (2015) CrossRef M. Kasahara, K. Saitoh, T. Sakamoto, N. Hanzawa, T. Matsui, K. Tsujikawa, F. Yamamoto, "Design of Three-Spatial-Mode Ring-Core Fiber", J. Lightwave Technol. 32, 1337 (2014). CrossRef P. Sillard, M. Bigot-Astruc, D. Boivin, H. Maerten, L. Provost, "Few-Mode Fiber for Uncoupled Mode-Division Multiplexing Transmissions", in 37th European Conference and Exposition on Optical Communications, (2011). CrossRef S. D. Jackson, S. Mossman, "Laser-induced changes on the complex refractive indices of phase-change thin film", Appl Opt. 42, 2702 (2003). CrossRef S. Unger, A. Schwuchow, J. Dellith, J. Kirchhof, "Optical properties of ytterbium/aluminium doped silica glasses", Opt Mater Express, 10, 907 (2020). CrossRef P. Honzatko, Y. Baravets, I. Kasik, O. Podrazky, "Wideband thulium–holmium-doped fiber source with combined forward and backward amplified spontaneous emission at 1600–2300 nm spectral band", Opt Lett. 39, 3650 (2014). CrossRef P. Miluski, M. Kochanowicz, J. M. Zmojda, A. Baranowska, M. Leśniak, D. Dorosz, K. Markowski, J. Dorosz, "Large mode area fibers for single-mode transmission near 2μm", Proc. SPIE 12142, (2022). CrossRef Y. Jung, Q. Kang, H. Zhou, R. Zhang, S. Chen, H. Wang, Y. Yang, X. Jin, F. P. Payne, S. Alam, D. J. Richardson, "Low-Loss 25.3 km Few-Mode Ring-Core Fiber for Mode-Division Multiplexed Transmission", J. Lightwave Technol. 35, 1363 (2017). CrossRef

APA, Harvard, Vancouver, ISO, and other styles

20

JPT staff, _. "E&P Notes (August 2021)." Journal of Petroleum Technology 73, no. 08 (August 1, 2021): 15–17. http://dx.doi.org/10.2118/0821-0015-jpt.

Full text

Abstract:

Energean Secures Rig for Multiwell Program off Israel Energean has signed a contract with Stena Drilling for an up to five-well drilling program offshore Israel, which is expected to target the derisking of unrisked prospective recoverable resources of more than 1 billion BOE. The contract is for the drilling of three firm wells and two optional wells using drillship Stena Icemax. The first firm well is expected to spud in early 2022. The firm wells are all expected to be drilled during 2022. “Our five-well growth program off-shore Israel, commencing in the first quarter of 2022, has the potential to double Energean reserve base with resource volumes that can be quickly, economically, and safely monetized,” said Mathios Rigas, chief executive of Energean. “Combined with first gas from our flagship Karish gas development project in mid-2022, the next 12 months are set to be truly transformational for Energean.” One of the firm wells is the Karish North development well. The scope includes re-entry, sidetracking, and completion of the previously drilled Karish North well and completion as a producer. The Karish North development will commercialize 1.2 Tcf of natural gas plus 31 million bbl of liquids and is expected to deliver first gas during the first half of 2023. The program also includes the Karish Main-04 appraisal well and the Athena exploration well, located in Block 12, directly between the Karish and Tanin leases. Athena is estimated to contain unrisked recoverable prospective resource volumes of 0.7 Tcf of gas plus 4 million bbl of liquids. Exxon Hits, Misses off Guyana ExxonMobil made another new discovery in the Stabroek Block offshore Guyana but came away empty with a well on the Canje block. The Longtail-3 well on the Stabroek block struck 230 ft of net pay, including newly identified reservoirs below those intervals found in the Longtail-1 probe. “Longtail-3, combined with our recent discovery at Uaru-2, has the potential to increase our resource estimate within the Stabroek block, demonstrating further growth of this world-class resource and our high-potential development opportunities offshore Guyana,” said Mike Cousins, senior vice president of exploration and new ventures at ExxonMobil. Exxon operates the 6.6-million-acre Stabroek Block as part of a consortium that includes Hess and China’s CNOOC. The new well was drilled 2 miles south of Longtail-1, which was drilled in 2018 and encountered 256 ft of oil-bearing sandstone. The Uaru-2 well in the Stabroek Block was announced in April. That well struck 120 ft of pay. While Stabroek drilling success continues, the operator suffered a set-back on the nearby Canje block and its Jabillo-1 well. The Stena Carron drillship reached a planned target depth of 6475 m; however the well failed to encounter commercial hydrocarbons. According to partner Eco Oil and Gas, the well was drilled to test Upper Cretaceous reservoirs in a stratigraphic trap. Drillship Stena Drillmax will next mobilize to drill the Sapote-1 prospect located in the south-eastern section of Canje, in a separate and distinct target from Jabillo. Sapote-1 lies approximately 100 km southeast of Jabillo and approximately 50 km north of the Haimara discovery in the Stabroek Block, which encountered 207 ft of gas-condensate-bearing sandstone reservoir. Erdogan Touts Turkish Black Sea Natural Gas Discoveries Turkey President Recep Tayyip Erdogan announced the discovery of new natural gas deposits in the Black Sea, where the country plans to start production in 2023. State energy company Tpao found 135 Bcm of gas at the Amasra-1 off-shore well, bringing the total amount of deposits discovered over the past year to 540 Bcm, according to Erdogan. Turkey has ramped up offshore exploration for hydrocarbons over the past few years. Last year, explorers found 405 Bcm of gas at the Tuna-1 well in Sakarya field. Turkey currently imports nearly all the 50 Bcm of gas it consumes annually. Equinor Hits Oil Near Visund Equinor struck oil in Production License 554 with a pair of wells at its Garantiana West prospect. Exploration wells 34/6-5 S and 34/6-5 ST2 were drilled some 10 km north-east of the Visund field, with the former encountering a total oil column of 86 m in the Cook formation. The latter well encountered sandstones in the Nansen formation, but did not encounter commercial hydro-carbons. Recoverable resources are esti-mated at between 8 and 23 million BOE. “This is the first Equinor-operated well in the production license, and the fifth discovery on the Norwegian continental shelf this year,” said Rune Nedregaard, senior vice president, exploration and production south. “The discovery is in line with our roadmap of exploring near existing infrastructure in order to increase the commerciality.” Well 34/6-5 S was drilled using Seadrill semisubmersible rig West Hercules. Equinor operates the discovery; partners include Var Energi and Aker BP. ExxonMobil Eyes Flemish Pass Well ExxonMobil is looking to secure a semi-submersible to complete the drilling of a deepwater wildcat in the Flemish Pass offshore eastern Canada. The operator began drilling the Hampden K-41 probe in the spring of last year using Seadrill semisubmersible rig West Aquarius, but the unit was pulled off the well soon thereafter for reasons unknown. ExxonMobil is currently prequalifying companies to supply a mobile offshore drilling unit to continue the well at Hampden in Exploration License (EL) 1165A. The operator is targeting a mid-year 2022 start to the probe to be drilled in around 1175 m of water, some 454 km from St. John’s, Newfoundland. Meanwhile, China’s CNOCC has wrapped up drilling on its Pelles prospect, its first exploration well offshore Newfoundland. The prospect, in about 1163 m of water, is located within license EL 1144. The wildcat was originally set to spud in early 2020 but was delayed due to impacts of the COVID-19 pandemic. The company confirmed that drilling operations onboard drillship Stena Forth were complete and the rig plugged and abandoned the well. The results of the well were not released. Equinor To Drop Mexican Offshore Leases Equinor will exit two Mexican deepwater blocks as part its upstream investment strategy to focus on assets offering rapid and strong returns. The two blocks located in the Salina Sureste basin were acquired in Mexico’s 1.4 bid round in an equal equity split with BP and TotalEnergies. Block 3, where Equinor holds a 33% operating interest, has water depths ranging from 900 to 2500 m. Block 1, where BP is the operator, has water depths ranging from 200 to 3100 m. Exploration commitments include a single well on each block, not yet drilled. The announcement to exit Mexico was made by Executive Vice President for E&P International Al Cook during the company’s Capital Markets Day event held in June. The company also unveiled plans to leave Nicaragua and Australia, as part of its upstream investment plans. Cook added that Equinor will only operate offshore assets moving forward and will no longer operate onshore, unconventional projects. The company will instead opt to partner with others on those projects. Equinor will also look to offload its exploration assets in the Austin Chalk play in the US and Terra Nova in Canada, he said. Var Energi Strikes North Sea Oil Var Energi has confirmed a discovery at its King and Prince exploration wells in the Balder area in the Southern North Sea. Success at the combined King and Prince exploration wells lifts preliminary estimates of recoverable oil equivalents between 60 and 135 million bbl. King/Prince was drilled in PL 027 by semisubmersible rig Scarabeo 8. The Prince well encountered an oil column of about 35 m in the Triassic Skagerrak formation within good to moderate reservoir sandstones, while the King well discovered a gas column of about 30 m and a light oil column of about 55 m with some thick Paleogene sandstone. An additional King appraisal side-track further confirmed a 40-m gas column and an oil column of about 55 m of which about 35 m are formed by thick and massive oil-bearing sandstone with excellent reservoir quality. The licensees consider the discoveries to be commercial and will assess tie-in to the existing infrastructure in the Balder area. The wells are located about 6 km north of the Balder field and 3 km west of the Ringhorne platform. Var Energi operates and holds a 90% stake of the license. Mime Petroleum holds the remaining 10%.

APA, Harvard, Vancouver, ISO, and other styles

21

Fitriningrun, Andriati, Andrey Hasiholan Pulungan, and Gilang Fajar Wijayanto. "The impacts of Acquisition on the Bidder’s Cash Flow Structure (The case of PT Central Sentosa Finance acquisition by PT Bank Central Asia)." Jurnal Manajemen 11, no. 2 (December 1, 2020): 126. http://dx.doi.org/10.32832/jm-uika.v11i1.3106.

Full text

Abstract:

The purpose of this study is to examine the impact of Merger and Acquisition (M&A) wave on constructing the capital structure. The conflict of government policies to assist the Small Medium Enterprises (SMEs) is in conflict with the other regulation which requires banks to meet the minimum Net Performing Loan (NPIL). This situation encourages the emergence of M&A wave in Indonesia. Numbers of banks do M&A as the option to accommodate the government regulations. Using the case of PT Central Sentosa Finance (CSF) acquisition by PT Bank Central Asia (BCA), this study examines the M&A impacts on the bidder’s capital structure when the acquisition due to the wave and government policy. The quantitative method is used to examine the impact of M&A on the company’s capital structure focusing the 2014 acquisition. The study contributes to the accounting in the area of transparency and capital issues. The statistical results show that the potential policies conflict drives the company to prioritize the selection of funding.

APA, Harvard, Vancouver, ISO, and other styles

22

Chadam, Aleksandra Anna. "Does the structure of the board of directors improve M&A performance?" International Journal of Synergy and Research 7 (March 2, 2019): 15. http://dx.doi.org/10.17951/ijsr.2018.7.0.15-31.

Full text

Abstract:

Purpose – The research focuses on examining which characteristics can raise or diminish board effectiveness in the context of M&A activities of companies.Design/methodology/approach – The nature of the research was quantitative, and the sample was selected purposefully. The data was retrieved from four databases: ThomsonOne, Eventus, Institutional Shareholder Platform (ISS) and Compustat. The final sample consisted of 2613 mergers and acquisitions and was selected by applying the following criteria: both the bidder and the target were US-based companies, the acquirer was a listed company, the acquisition announcement took place over the period 2008 – 2017, the deal value exceeded USD 1 million, the transaction resulted in a control gain over the target company. M&A performance was assessed using cumulative abnormal return (CAR) method, while the board influence was examined using ordinary least square (OLS) regression. Five hypotheses regarding the influence of board independence, gender diversity, board size, CEO duality and type of elections were tested in the research.Findings – Two out of five hypotheses were confirmed in the study. Board independence and board classification increase bidders’ CARs over the deal announcement period.Research limitations/implications: The main limitation is related to the measurement of M&A performance, which is relatively difficult to quantify. Moreover, the method of selection of the sample, especially a higher proportion of companies from certain industries could affect the outcomes and underestimate the impact of gender diversity. Further research could investigate the deals in the long-term perspective and apply different criteria in the sample selection process.Practical implications: The outcome of this study is of importance to acquisitive and non-acquisitive companies by aiding them in finding an optimal board structure, which can effectively monitor and motivate the CEO, leading to profitable decisions concerning not only M&A but all major investments.Originality/value: The study investigates the topic of board effectiveness in the M&A context, which the research coverage is still very limited. The study covers five board characteristics and several control variables to increase the robustness of the results and ensure their correct interpretation. Finally, the sample consists of the most recent data, which enables to draw up-to-date conclusions that consider constantly developing corporate governance law and trends regarding the board structure and composition.

APA, Harvard, Vancouver, ISO, and other styles

23

CHEN, Penny, Trishla GOLECHHA, Greeshma GADDAM, Sharika PINNADUWA, Farjana YASMIN, Aarshiya, Nehal NAIK, Preethi SELVARAMANUJAM, Sanya KALRA, and Sally CATT. "Warming Oocytes with a Universal Warming Medium and Protocol is as Good as the Company Media and Protocols." Fertility & Reproduction 04, no. 03n04 (September 2022): 175. http://dx.doi.org/10.1142/s2661318222740863.

Full text

Abstract:

Background: A universal warming media and protocol would simplify exchange and use of oocytes and embryos between different IVF centres. Aim: The aim of this study was to compare a universal warming medium and protocol (Parmegiani et al, 2014 RBMonline 28, 614-23) with 3 other warming media and protocols which were used with their corresponding vitrification media (2 commercial, one in house) measuring survival (pre and post insemination combined), fertilization and blastocyst rate. Method: This was a prospective study on 300 mature cumulus-free F1 mouse oocytes divided between three vitrification protocols, SAGE™ vitrification (S), RapidVit™ Omni by Vitrolife (V), and the in house ‘MCE-Trehalose’ (M) designed for mouse embryos. Oocytes for each vitrification group (S,V & M) were divided equally to be warmed either by the corresponding warming protocols (S/S, V/V & M/M and or the universal warming protocol (S/U, V/U and M/U). Surviving oocytes were inseminated in vitro with 250,000 motile sperm/ml 2h after warming (18 oocytes were not retrieved post-warm). Results: V/V (25%), V/U (42%) had significantly lower survival than all other groups S/S (72%), S/U (76%), M/M (91%), M/U (82%; P<0.01, Fishers Exact), but no other differences were observed. Fertilization rates [S/S (43%), S/U (40%), V/V (62%), V/U (57%), M/M (59%), M/U (45%)] and blastocyst rates [S/S (61%), S/U (41%), V/V (60%), V/U (75%), M/M (54%), M/U (60%)] did not differ. Conclusion: In conclusion, the universal warming protocol had similar outcomes to the other 3 warming protocols, thus shows promise for warming oocytes vitrified by any vitrification protocol within and between species. Also, demonstrated is that IVF can be used for vitrified oocytes, and thus can provide an option tother than using ICSI clinically, but more studies finding the most suitable clinical media and protocol are needed.

APA, Harvard, Vancouver, ISO, and other styles

24

Kamadita, Putri Adisti, and Nujmatul Laily. "The Development of M-Learning Based on Integration-Interconnection of The Accounting Cycle of Trading Company." Journal of Accounting and Business Education 3, no. 1 (September 1, 2018): 56. http://dx.doi.org/10.26675/jabe.v3i1.11557.

Full text

Abstract:

This study aims to produce a mobile learning application based on the topic of integration-interconnectionofthe trading company. The application is useful as an alternative to independent learning that can support the learning of accounting students .This research was a development research which refers to the development procedure of Borg and Gall which was modified into seven steps. Data in this study were collected using a questionnaire. The results of the study showed that the percentage of eligibility of the material expert validator was 73%, the media expert validator was 98%, the integration-interconnection expert validator was 75%, and the respondent was 79%. The average percentage of eligibility is 81 %. This number means that the application is very feasible to use. Some suggestions that can be given for further development of the application are by making indicators of specific expert validation measurements with supporting references; provide competency updates to the application and add new practice questions; the presentation of the verses of the Qur'an and Hadith can be added so that the students' knowledge of the relationship between the Qur'an, Hadith,and accounting becomes wider; as well as product testing, so that the level of effectiveness of learning media products can be known.

APA, Harvard, Vancouver, ISO, and other styles

25

Sofie, Sofie, Ari Prihartini, and Rinda Liana. "Intellectual Capital Terhadap Nilai Pasar Dan Kinerja Keuangan Perusahaan Dengan Value Added Intellectual Capital (Studi Pada Perusahaan Manufaktur di Bursa Efek Indonesia Tahun 2008-2011)." JURNAL INFORMASI, PERPAJAKAN, AKUNTANSI, DAN KEUANGAN PUBLIK 7, no. 2 (May 7, 2019): 43. http://dx.doi.org/10.25105/jipak.v7i2.4499.

Full text

Abstract:

This study aims to ident6 and analyze the effect of intellectual capital as one of the company's intangible assets to market value and financial performance.of the company-manufacturing companies using the Value Added Intellectual Capital (VAIC m). The analysis method used is multiple panels because the structure of the data used in this research is the data panel. The results of the hypothesis theory shows that the intellectual capital has significant effect on the market value and performance of the company. The three components of intellectual capital, as the physical capital efficiency, human capital and structural capital efficiency, have a positive effect on firm value and performance of companies that dproksi by ROA, ATO, ROE and OI / S. So do the results of statistical tests, except for the efficiency of the human capital and structural capital efficiency ROE against Of / S. The results show that intellectual capital is a factor that is very important and significant effect on the quality of the company which in turn directly affects firm value andfinancial performance of the company.

APA, Harvard, Vancouver, ISO, and other styles

26

Fitriani, Rika, Guskarnali Guskarnali, and Delita Ega Andini. "Analisis Pengaruh Geometri Jalan Tambang Dari Front Penambangan ke Stockpile Terhadap Keselamatan Kerja PT Caritas Energi Indonesia Sarolangun Jambi." MINERAL 5, no. 2 (October 1, 2020): 17–22. http://dx.doi.org/10.33019/mineral.v5i2.3071.

Full text

Abstract:

PT Caritas Energi Indonesia (CEI) is a company engaged in coal mining in Sarolangun Jambi. Based on the work accident data in the last 5 years of PT Caritas Energi Indonesia on the hauling coal getting road using dump truck transport Equipment Scania 380 P that resulted casualty and inflicted loss for the company both in terms of equipment repair and treatment of victims. The method on this research is to use quantitative data to calculate the width of straight road for sixty one segments, the width of bend road for fourteen segments, calculating the superelevation for fourteen segments, calculating hauling road slope (grade) for sixty one segments, calculating the cross slope for sixty one segments, analyzing the effect of road geometry on Occupational Health and Safety. The width of the straight road is 7 m for one line and 11 m for two lines, all segments were qualified, except Segment 0+400, Segment 0+700, Segment 1+600, thereforeit is necessary to increase the width of road to fit the standard, the width of the bend roadis 8 m for a single line and 13 m for two lines, all segments were qualified, exceptSegment 0+500, Segment 1+000 and Segment 4+100, superelevationbased on standard is 4%, not all of the superelevations were qualified so it needs to increase the width of the bend road so that it might avoid the centrifugal force while passing through the bend, all the grade of segmentswere qualified. PT Caritas Energi Indonesia didn’t have cross slope so the company needs to pay attention and make cross slope according to the standard of 40 mm/m. The geometry of the mining road of PT Caritas Energi Indonesia weren’t qualified, it might effectedwork accident so that it needs improvement accordance with standards

APA, Harvard, Vancouver, ISO, and other styles

27

Dignass, A., S. Danese, K. Matsuoka, M. Ferrante, M. Long, I. Redondo, T. H. Gibble, et al. "A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (March 1, 2023): 29–31. http://dx.doi.org/10.1093/jcag/gwac036.185.

Full text

Abstract:

Abstract Background Mirikizumab (miri) improved symptom control in a Phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study at Week (W)12, in patients (pts) with moderately-to-severely active ulcerative colitis (UC; LUCENT-1). Purpose This analysis assessed sustained symptom control during the maintenance phase through W40 (W52 of continuous therapy), among pts who were induced into clinical response with miri. Method During the 40W maintenance study (LUCENT-2), pts (N=544) who achieved clinical response to miri 300mg Q4W by W12 of induction, were re-randomized 2:1 to subcutaneous (SC) miri 200mg (n=365) or PBO Q4W (n=179). We evaluated sustained control of stool frequency (SF), rectal bleeding (RB), bowel movement urgency (BU) and abdominal pain (AP). The proportion of pts achieving SF Remission (defined as SF=0, or SF=1 with a ≥1-point decrease from induction baseline [BL]), RB Remission (RB=0), Symptomatic Remission (both SF and RB Remission), Stable Maintenance of Symptomatic Remission (defined as pts in Symptomatic Remission for at least 7 out of 9 visits from W4 to W36 and also at Week 40 among pts in Symptomatic Remission and Clinical Response at the end of LUCENT-1), and AP Improvement (Numeric Rating Scale [NRS] pain score ≥30% improvement from BL in pts with baseline AP NRS ≥3) were assessed. BU NRS change from baseline, and the proportion of pts achieving BU Remission (NRS 0 or 1 in pts with BU NRS ≥3 at baseline) were evaluated. Result(s) A greater proportion of miri-treated pts achieved SF Remission, RB Remission and Symptomatic Remission compared to PBO at W40 (Table), with significant differences observed from W8 of LUCENT-2 (p=0.042; p=0.004; p=0.036, respectively) and maintained through W40. Miri-treated pts had a significantly higher percentage of Stable Maintenance of Symptomatic Remission (p<0.001). Pts in the miri-treatment group had a significantly greater mean reduction in BU NRS change from induction BL starting at W12 (p=0.034) onwards compared to PBO (Table). Pts assigned to miri accrued an additional 13.6 percentage-point benefit in BU Remission during the first 8W of maintenance therapy and achieved a significant greater improvement at W40 compared to PBO (p<0.001, Table). Similarly, AP was significantly improved for the miri-treated group starting at W16 (p=0.034) onwards compared to PBO. Image Conclusion(s) Miri provides sustained control of UC symptoms including BU, RB, and SF compared to PBO in pts with moderately to severely active UC. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Eli Lilly and Company Disclosure of Interest A. Dignass Consultant of: AbbVie, Abivax, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb (Celgene), Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Pharmacosmos, Roche, Sandoz/Hexal, Takeda, Tillotts Pharma AG, and Vifor Pharma; has received lecture fees or honoraria from: AbbVie, Amgen, Bristol Myers Squibb, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos, High5Md, Janssen, Materia, Merck Sharp & Dohme, Pfizer, Sandoz, Takeda, Tillotts Pharma AG, and Vifor Pharma, S. Danese Consultant of: AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Mundipharma, Mylan, Pfizer, Roche, Sandoz Sublimity, Takeda, TiGenix, UCB Pharma, and Vifor Pharma, Speakers bureau of: AbbVie, Amgen, Ferring Pharmaceuticals, Gilead Sciences, Janssen, Mylan, Pfizer, and Takeda, K. Matsuoka Grant / Research support from: AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Kyowa Kyorin, Mitsubishi Tanabe, Mochida Pharmaceutical, and Zeria Pharmaceutical Nippon; lecture fees from: AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Kyowa Kyorin, Mitsubishi Tanabe, Mochida Pharmaceutical, Takeda, and Zeria Pharmaceutical Nippon, M. Ferrante Grant / Research support from: AbbVie, Amgen, Biogen, Janssen Cilag, Pfizer, Takeda, and Viatris, Consultant of: AbbVie, Boehringer Ingelheim, Celltrion, Eli Lilly and Company, Janssen Cilag, Medtronic, Merck Sharp & Dohme, Pfizer, Regeneron, Sandoz, Takeda, and Thermo Fisher Scientific, Speakers bureau of: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Janssen, Lamepro, Medtronic, Merck Sharp & Dohme, Mylan, Pfizer, Samsung Bioepis, Sandoz, Takeda, and Thermo Fisher Scientific, M. Long Consultant of: AbbVie, Bristol Myers Squibb, Calibr, Eli Lilly and Company, Genentech, Janssen, Pfizer, Prometheus Biosciences, Roche, Takeda, TARGET PharmaSolutions, and Theravance Biopharma, I. Redondo Employee of: Eli Lilly and Company, T. Gibble Employee of: Eli Lilly and Company, R. Moses Employee of: Eli Lilly and Company, X. Li Employee of: Eli Lilly and Company, N. Morris Employee of: Eli Lilly and Company, C. Milch Employee of: Former employee, was employed at Eli Lilly and Company at the time of study, M. Abreu Grant / Research support from: Pfizer, Prometheus Biosciences, and Takeda, Consultant of: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Janssen, Microba Life Sciences, Prometheus Biosciences, UCB Pharma, and WebMD, Speakers bureau of: Alimentiv, Intellisphere LLC (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda, J. Jones: None Declared

APA, Harvard, Vancouver, ISO, and other styles

28

Bechrifa, Emna, Nihel Khouja, Emna Baraketi, Asma Koubaa, Naourez Ben Fatma, Amira Belkahla, Saloua Ismail, et al. "P-359 EVALUATION OF EXPOSURE TO LOW DOSES OF LEAD IN THE CIRCUIT BOARD MANUFACTURING INDUSTRY." Occupational Medicine 74, Supplement_1 (July 1, 2024): 0. http://dx.doi.org/10.1093/occmed/kqae023.0976.

Full text

Abstract:

Abstract Introduction The toxicity of lead has been known since antiquity, and it has become clear that low levels of lead are likely to cause problems that are certainly less important but worrying. Objectives: To assess occupational exposure to lead in the electronic circuit board industry and describe the occupational and clinical characteristics of workers exposed to low doses of lead. Methods A cross-sectional descriptive study was conducted among workers of two electronic card manufacturing companies in Tunisia using a questionnaire. Results Fifty-two workers were exposed to lead. The mean age was 39.12 ± 8.7 years. Women account for 67% of the workforce. They were general workers in 90% of cases. Lead in air for company 1 ranged from non-detectable to 0.069 mg/m₃ and for company 2 the value was less than 0.01 mg/m₃. The blood lead levels of our employees varied between 10 and 75µg/l with a median of 16µg/l. At the digestive level, they reported anorexia (27%), weight loss (17%), abdominal colic (25%), and constipation (17%). Sleep disorders were found, such as frequent nocturnal awakenings (31%), insomnia upon awakening (25%), and insomnia upon falling asleep (23%). Employees had memory problems such as impaired ability to memorize a new fact (27%) and impaired ability to retrieve a memory (12%), mood disorders such as sadness (19%) and anxiety (25%) and behavioral disorders manifested by irritability (39%) and aggressiveness (19%). Discussion We highlighted exposure to low doses of lead in the electronic card sector. Conclusion Various symptoms were reported, highlighting the importance of strengthening preventive strategies.

APA, Harvard, Vancouver, ISO, and other styles

29

JPT staff, _. "E&P Notes (December 2020)." Journal of Petroleum Technology 72, no. 12 (December 1, 2020): 16–17. http://dx.doi.org/10.2118/1220-0016-jpt.

Full text

Abstract:

China Shale-Gas Field Sets Production Record Sinopec recorded China’s highest daily output of shale gas at 20.62 million cubic meters (Mcm) at its Fuling shale-gas field in Chongqing, China, a key gas source for the Sichuan-East gas pipeline. The first major commercial shale-gas project in China, Fuling has continuously broken records for the shortest gasfield drilling cycle while significantly increasing the drilling of high-quality reservoirs covering more than 3 million m, according to Sinopec. Gasfield production construction was also expanded to raise production capacity. The company said the field maintains a daily output of 20 Mcm, producing an estimated 6.7 Bcm per year. Apache and Total Plan Suriname Appraisals Apache filed appraisal plans for its Maka and Sapakara oil discoveries in block 58 offshore Suriname. The company said another submission is expected for Kwaskwasi, the largest find in the block, by the end of the year. Operations continue for Keskesi, the fourth exploration target. There are plans to drill a fifth prospect at Bonboni in the North-Central portion of the concession. Partner company Total is assuming operatorship of the block ahead of next year’s campaigns. BP Emerges as Sole Bid for Offshore Canada Parcels BP was the only operator to place a bid in the Canada-Newfoundland and Labrador Offshore Petroleum Board (C-NLOPB) Call for Bids NL20-CFB01, which offered 17 parcels (4,170,509 hectares) in the eastern Newfoundland region. The successful bid was for Parcel 9 (covering 264,500 hectares) for $27 million in work commitments from BP Canada Energy Group. Subject to BP satisfying specified requirements and receiving government approval, the exploration license will be issued in January 2021. No bids were received for the remaining 16 parcels, which may be reposted in a future Call for Bids. Criteria for selecting a winning bid is the total amount the bidder commits to spend on exploration of the parcel during the first period of a 9-year license, with a minimum acceptable bid of $10 million in work commitments for each parcel. Beach Energy To Drill Otway Basin Well Beach Energy plans to drill at its Artisan-1 well about 32 km offshore Victoria, Australia, in the Otway basin, before the end of 2021. The well, located on Block Vic/P43, was to be spudded in 1H 2020 but was delayed due to COVID-19. The timeframe for drilling was confirmed by the National Offshore Petroleum Safety and Environmental Management Authority, which also said Beach is keeping open the option to suspend the well and develop it, pending reservoir analysis. Anchors, mooring chains, and surface buoys have already been laid for the well, which is in a water depth of approximately 71 m. The well is expected to take approximately 35–55 days to drill, depending on the final work program and potential operational delays. Diamond Offshore’s semisubmersible Ocean Onyx was contracted for the drilling program. Artisan is the first of Beach’s planned multiwell campaigns, which also include development wells at the Geographe and Thylacine fields. Hess Completes Sale of Interest in Gulf of Mexico Field Hess completed the sale of its 28% working interest in the Shenzi Field in the deepwater Gulf of Mexico (GOM) to BHP, the field’s operator, for $505 million. Shenzi is a six-lease development structured as a joint ownership: BHP (operator, 44%), Hess (28%), and Repsol (28%). The acquisition would bring BHP’s working interest to 72%, adding approximately 11,000 BOE/D of production (90% oil). The sale is expected to close by December 2020. Hess CEO John Hess said proceeds from the sale will help fund the company’s investment in Guyana. Greenland Opens New Offshore Areas Greenland opened three new offshore areas for application of oil and gas exploitation licenses off West Greenland. The areas are Baffin Bay, Disko West, and Davis Strait. The country also said it is working on an oil strategy to reduce geological uncertainty by offering an investment package to companies that engage in its Open Door Procedures. The procedures are a first-mover advantage to remove national oil company Nunaoil, as a carried partner, reducing turnover and surplus royalties. It is estimated to reduce the government take by 51.3% to 40.6%. Shell and Impact Oil & Gas Agree to South Africa Farmout Africa Oil announced Impact Oil & Gas entered into two agreements for exploration areas offshore South Africa. The company has a 31.10% share-holding in Impact, a privately owned exploration company. Impact entered into an agreement with BG International, a Shell subsidiary, for the farm-out of a 50% working interest and operatorship in the Transkei and Algoa exploration rights. Shell was also granted the option to acquire an additional 5% working interest should the joint venture (JV) elect to move into the third renewal period, expected in 2024. Algoa is located in the South Outeniqua Basin, east of Block 11B/12B, containing the Brulpadda gas condensate discovery and where Total recently discovered gas condensate. The Transkei block is northeast of Algoa in the Natal Trough Basin where Impact has identified highly material prospectivity associated with several large submarine fan bodies, which the JV will explore with 3D seismic data and then potential exploratory drilling. Impact and Shell plan to acquire over 6,000 km² of 3D seismic data during the first available seismic window following completion of the transaction. This window is expected to be in the Q1 2022. After the closing of the deal, Shell will hold a 50% interest as the operator and Impact will hold 50%. Impact also entered into an agreement with Silver Wave Energy for the farm-in of a 90% working interest and operatorship of Area 2, offshore South Africa. East and adjacent to Impact’s Transkei and Algoa blocks, Area 2 complements Impact’s existing position by extending the entire length of the ultradeepwater part of the Transkei margin. Together, the Transkei and Algoa Blocks and Area 2 cover over 124,000 km2. Area 2 has been opened by the Brulpadda and Luiperd discoveries in the Outeniqua Basin and will be further tested during 2021 by the well on the giant Venus prospect in ultradeepwater Namibia, where Impact is a partner. Impact believes there is good evidence for this Southern African Aptian play to have a common world-class Lower Cretaceous source rock, similar excellent-quality Apto-Albian reservoir sands, and a geological setting suitable for the formation of large stratigraphic traps. Following completion of the farm-in, Impact will hold 90% interest and serve as the operator; Silver Wave will hold 10%. Petronas Awards Sarawak Contract to Seismic Consortium The seismic consortium comprising PGS, TGS, and WesternGeco was awarded a multiyear contract by Petronas to acquire and process up to 105,000 km2 of multisensor, multiclient 3D data in the Sarawak Basin, offshore Malaysia. The contract award follows an ongoing campaign by the consortium in the Sabah offshore region, awarded in 2016, in which over 50,000 km2 of high-quality 3D seismic data have been acquired and licensed to the oil and gas industry to support Malaysia license round and exploration activity. The Sarawak award will allow for a multiphase program to promote exploration efforts in the prolific Sarawak East Natuna Basin (Deepwater North Luconia and West Luconia Province). The consortium is planning the initial phases and is engaging with the oil and gas industry to secure prefunding ahead of planned acquisition, covering both open blocks and areas of existing farm-in opportunities. Total Discovers Second Gas Condensate in South Africa Total made a significant second gas condensate discovery on the Luiperd prospect, located on Block 11B/12B in the Outeniqua Basin, 175 km off the southern coast of South Africa. The discovery follows the adjacent play-opening Brulpadda discovery in 2019. The Luiperd-1X well was drilled to a total depth of about 3,400 m and encountered 73 m of net gas condensate pay in well-developed, good-quality Lower Cretaceous reservoirs. Following a coring and logging program, the well will be tested to assess the dynamic reservoir characteristics and deliverability. The Block 11B/12B covers an area of 19,000 km2, with water depths ranging from 200 to 1800 m. It is operated by Total with a 45% working interest, alongside Qatar Petroleum (25%), CNR International (20%), and Main Street, a South African consortium (10%). The Luiperd prospect is the second to be drilled in a series of five large submarine fan prospects with direct hydrocarbon indicators defined utilizing 2D and 3D seismic data. BP Gas Field Offshore Egypt Begins Production BP started gas production from its Qattameya gasfield development ‎offshore Egypt in the North Damietta offshore concession. Through BP’s joint venture Pharaonic Petroleum Company working with state-owned Egyptian Natural Gas Holding Co., the field, which is ‎expected to produce up to 50 MMcf/D, was developed through a one-well subsea development and tieback to existing infrastructure.‎ Qattameya, whose discovery was announced in 2017, is located approximately 45 km west ‎of the Ha’py platform, in 108 m of water. It is tied back to the Ha’py and Tuart field ‎development via a new 50-km pipeline and connected to existing subsea ‎utilities via a 50-km umbilical. ‎BP holds 100% equity in the North Damietta offshore concession in the East Nile Delta. ‎Gas production from the field is directed to Egypt’s national grid.

APA, Harvard, Vancouver, ISO, and other styles

30

Kurniawati, Elfira Pipit, and Sawidji Widoatmodjo. "Readiness For Organizational Change: Workplace and Individual Factors At PT TBK (JV Company)." Asian Journal of Social and Humanities 2, no. 03 (December 23, 2023): 1917–25. http://dx.doi.org/10.59888/ajosh.v2i03.205.

Full text

Abstract:

The merger & acquisition (M&A) process with foreign companies can cause changes in the company, ranging from changes in structure to processes and ways of working in the company. This study aims to determine the influence of workplace factors in the form of organizational commitment, organizational culture, organizational support and individual factors in the form of job satisfaction, work attachment and affective commitment to employee readiness to face change. Data collection in this study used the probability sampling method. The number of participants obtained in this study was 156 employees at the head office of PT Tbk Organization culture, organizational commitment, job satisfaction, work attachment and individual commitment (affective commitment) had a significant influence on readiness for organizational change (p = 0.00). Organizational support had no significant effect on readiness for organizational change (p = 0.053). Organizational culture factors are the most influential factors on readiness for organizational change.

APA, Harvard, Vancouver, ISO, and other styles

31

Pehlivanlı, Edib Ali. "THE EFFECT OF DECARBONIZATION SIGNAL ON JOB APPLICATION INTENTION: A PARALLEL MEDIATION MODEL." Kafkas Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi 15, no. 29 (June 28, 2024): 54–75. http://dx.doi.org/10.36543/kauiibfd.2024.003.

Full text

Abstract:

This study examines how including decarbonization signals in job postings influences prospective job seekers' perceptions and intentions. Using an experimental approach with senior students (N=334), the research explored the effects of decarbonization signals on organizational attractiveness, person-organization fit, and intention to apply for a job vacancy. Participants viewed job postings either with or without explicit decarbonization signals from a fictitious company, "Victory Holding". Results confirmed that decarbonization signals significantly enhanced perceptions of environmental sensitivity (M=4.02 vs. M=3.51, p<.001), validating the manipulation. Mediation analysis revealed that while decarbonization signals did not directly affect job application intentions (β=.008, p=.831), both organizational attractiveness (β=.20, p<.001) and person-organization fit (β=.16, p=.003) mediated this relationship. Theoretical implications highlight organizational attractiveness and person-organization fit as parallel mediators in the relationship between environmental signals and job application intentions. This study underscores the strategic potential of decarbonization signals in enhancing organizational attractiveness to environmentally conscious talent.

APA, Harvard, Vancouver, ISO, and other styles

32

Van Beers, Eduard J., Hanny Al-Samkari, Rachael F. Grace, Wilma Barcellini, Andreas Glenthoej, Malia P. Judge, Penelope A. Kosinski, et al. "Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency." Blood 138, Supplement 1 (November 5, 2021): 2005. http://dx.doi.org/10.1182/blood-2021-147317.

Full text

Abstract:

Abstract Background: Pyruvate kinase (PK) deficiency is a rare hereditary disease resulting in chronic hemolytic anemia, which is associated with serious complications, including iron overload, regardless of transfusion status. Ineffective erythropoiesis is linked to iron overload in patients (pts) with hemolytic anemias. Mitapivat is a first-in-class, oral, allosteric activator of the red blood cell PK enzyme (PKR) that has demonstrated improvement in hemoglobin (Hb), hemolysis, and transfusion burden in pts with PK deficiency. This analysis assessed the effect of mitapivat on markers of erythropoiesis and iron overload in pts with PK deficiency enrolled in 2 phase 3 studies, ACTIVATE (NCT03548220) and ACTIVATE-T (NCT03559699), and the long-term extension (LTE) study (NCT03853798). Methods: In ACTIVATE (double-blind, placebo-controlled study), 80 pts (age ≥ 18 years [yrs]) with a confirmed diagnosis of PK deficiency who were not regularly transfused (≤ 4 transfusion episodes in the prior yr; none in the prior 3 months) were randomized to receive mitapivat or placebo. In ACTIVATE-T (open-label, single-arm study), 27 pts (age ≥ 18 yrs) with a confirmed diagnosis of PK deficiency who were regularly transfused (≥ 6 transfusion episodes in the prior yr) were treated with mitapivat. Pts who completed either trial (24 weeks [wks] [ACTIVATE], 40 wks [ACTIVATE-T]) were eligible to continue in the LTE. Erythropoiesis markers included erythropoietin (EPO), erythroferrone, reticulocytes, and soluble transferrin receptor (sTfR). Markers of iron overload included hepcidin, iron, transferrin saturation (TSAT), ferritin, and liver iron concentration (LIC) by magnetic resonance imaging (MRI). In the LTE all pts received mitapivat. Pts from ACTIVATE were categorized into either the mitapivat-to-mitapivat arm (M/M) or the placebo-to-mitapivat arm (P/M). The ACTIVATE-T/LTE analysis includes pts who achieved transfusion-free status in ACTIVATE-T. The ACTIVATE/LTE analysis assessed change in markers from baseline (BL) over time in both study arms. Results: Eighty pts were included in the ACTIVATE/LTE analysis (M/M = 40; P/M = 40). Pts in both arms had abnormal BL erythropoiesis markers consistent with underlying ineffective erythropoiesis, and BL abnormal markers of iron overload. In the M/M arm, mean (SD) EPO, erythroferrone, reticulocytes, and sTfR decreased from BL to Wk 24 of mitapivat treatment by -32.9 IU/L (62.47), -9834.9 ng/L (13081.15), -202.0 10 9/L (246.97), and -56.0 nmol/L (82.57), respectively, while they remained stable or increased in the P/M arm on placebo (Figure). Twenty-four wks after starting mitapivat in the LTE (Wk 48 post BL), pts in the P/M arm had comparable beneficial decreases in mean (SD) EPO, erythroferrone, reticulocytes, and sTfR of -11.6 IU/L (30.74), -9246.1 ng/L (8314.17), -283.7 10 9/L (374.27), and -38.7 nmol/L (48.37), respectively. Improvements in hepcidin, iron, TSAT, and LIC were also observed with mitapivat treatment; ferritin remained stable (Table). Mean (SD) hepcidin increased in the M/M arm at Wk 24 and in the P/M arm 24 wks after starting mitapivat (Wk 48 post BL). At Wk 24, mean (SD) iron and TSAT, and median (Q1, Q3) LIC decreased in the M/M arm, while they increased on placebo. In the P/M arm, iron, TSAT, and LIC decreased 24 wks after starting mitapivat (Wk 48 post BL). Transfusion-free responders from ACTIVATE-T (n = 6) also experienced improvements in markers of erythropoiesis and iron overload in the LTE. Conclusions: In addition to improving Hb, hemolysis, and transfusion burden, data from ACTIVATE, ACTIVATE-T, and the LTE study indicate that activation of PKR with mitapivat improves markers of ineffective erythropoiesis and iron homeostasis in PK deficiency, thereby decreasing iron overload in these pts. Mitapivat has the potential to become the first approved therapy in PK deficiency with beneficial effect on iron overload. Figure 1 Figure 1. Disclosures Van Beers: Agios Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; RR Mechatronics: Research Funding; Pfizer: Research Funding. Al-Samkari: Amgen: Research Funding; Argenx: Consultancy; Rigel: Consultancy; Novartis: Consultancy; Dova/Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding; Moderna: Consultancy. Grace: Agios: Research Funding; Dova: Membership on an entity's Board of Directors or advisory committees, Research Funding; Principia: Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding. Barcellini: Bioverativ: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Alexion Pharmaceuticals: Honoraria; Novartis: Honoraria; Agios: Honoraria, Research Funding. Glenthoej: Bluebird Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Calgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alexion: Research Funding; Novo Nordisk: Honoraria. Judge: Agios Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Kosinski: Agios Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Xu: Agios Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Beynon: Agios Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. McGee: Agios Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Porter: La Jolla Pharmaceuticals: Honoraria; Protagonism: Honoraria; Agios: Consultancy, Honoraria; bluebird bio, Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene (BMS): Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Vifor: Honoraria, Membership on an entity's Board of Directors or advisory committees; Silence Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees. Kuo: Celgene: Consultancy; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria; Alexion: Consultancy, Honoraria; Bioverativ: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Research Funding; Bluebird Bio: Consultancy; Apellis: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

33

Mammadov, Arif, Nizami Ismayilov, Elxan Mammadov, and Muxtar Huseynov. "Study of the Possibility of Production of Continuously Cast Billets from Shipbuilding Steels." Key Engineering Materials 979 (April 5, 2024): 73–80. http://dx.doi.org/10.4028/p-8ys0gg.

Full text

Abstract:

The importance of creating specialized production sites to meet the needs of shipbuilding and ship repair enterprises of Azerbaijan in metal billets is substantiated. Technical, technological and organizational measures for the specialization of the existing production sites of Baku Steel Company LLC for the production of shipbuilding steels are recommended. The ways of mastering the production of continuously cast billets and sheet-rolling technologies from shipbuilding steels are shown.For this purpose, the need to install a continuous casting machine (CCM) in Baku Steel Company LLC is substantiated and the advantages of manufacturing steel billets on this machine are shown. It is determined that in order to reduce the overall dimensions of the caster, its radius of curvature should be 10.2 m. It is shown that the rational value of the radius of curvature reduces the probability of defects on the blanks during crystallization and makes it possible to obtain blanks of various profiles.It is shown that the combined use of EMF and hydrocarbons can reduce the defects of blanks by 2-3 times, increase the zones of equiaxial crystals by 50-80%, significantly reduce axial porosity and liquation, increase the casting speed of liquid steel by 20-30% and reduce the metal consumption of equipment by 2 times. The introduction of technologies for electromagnetic mixing and vacuuming of liquid steel makes it possible to expand the production of alloy steels for the needs of shipbuilding and ship repair enterprises.

APA, Harvard, Vancouver, ISO, and other styles

34

Chen, Ming. "PENGARUH UKURAN DEWAN KOMISARIS DAN KEPEMILIKAN ASING TERHADAP LUAS PENGUNGKAPAN CSR." EL Muhasaba Jurnal Akuntansi 10, no. 2 (July 29, 2019): 141. http://dx.doi.org/10.18860/em.v10i2.6721.

Full text

Abstract:

This study aims to determine the effect of the size of the Board of Commissioners and Foreign Ownership on the Extent of CSR Disclosure. This study was tested using multiple regression. The sample is a Manufacturing company listed on the Indonesia Stock Exchange. The study period for 3 years fr: m 2014 until 2016. The results of the study found that the size of the board of commissioners influences the extent of CSR disclosure while Foreign Ownership does not affect the wide range of CSR disclosure.

APA, Harvard, Vancouver, ISO, and other styles

35

Agapov, Mikhail G. "THE ADMIRAL AND THE MERCHANTS: FROM THE HISTORY OF COMMERCIAL AND INDUSTRIAL DEVELOPMENT OF THE PECHORA AND OB IN THE 1840S–1860S." Ural Historical Journal 80, no. 3 (2023): 182–89. http://dx.doi.org/10.30759/1728-9718-2023-3(80)-182-189.

Full text

Abstract:

The article considers a little examined aspect of the history of Russian entrepreneurship associated with the risky nature of commercial and industrial development of the Russian imperial northern periphery. The central plot of the study is the business partnership of the famous navigator and scientist, Admiral P. I. Kruzenshtern and prominent figures of the Russian northern entrepreneurship of gold miners and merchants V. N. Latkin and M. K. Sidorov within the framework of the Pechora-Ob Company formed by them in 1858 for the development of industry, shipping and trade in the Northern Ocean along the Pechora and Ob rivers. Based on a detailed analysis of the company’s design, organizational and logistics activities, it is concluded that the reasons for its collapse in the mid-1860s cannot be explained only by objective factors noted in historiography such as insufficient support from the state, opposition from officials and competitors. The bankruptcy of the company was largely due to subjective reasons. Thus, the idea of the excessive wealth of natural resources of Russia’s North and the possibility of their easy extraction prevented P. I. Kruzenshtern, V. N. Latkin and M. K. Sidorov from adequately assessing the complexity of the organizational and logistical tasks facing them. The propensity of the partners to being visionary, their reliance on luck and mutual accusations of the failure of the enterprise without analyzing their own miscalculations are no less important part of the history of the Pechora-Ob company. Without taking account of such subjective factors in the implementation of innovative commercial projects, the enormous experience of domestic northern entrepreneurship cannot be analyzed comprehensively and used by the next generations of entrepreneurs in full measure.

APA, Harvard, Vancouver, ISO, and other styles

36

SALAH, TAREQ, MARWA AL-BADRI, ABD ALMASIH BARBAR ASKAR, ABDELRAHMAN KHATER, SHILTON E. DHAVER, ADHAM MOTTALIB, and OSAMA HAMDY. "408-P: Long-Term Improvement in Renal Function following Intensive Lifestyle Intervention in Patients with Diabetes and Obesity—A 15-Year Longitudinal Study." Diabetes 73, Supplement_1 (June 14, 2024). http://dx.doi.org/10.2337/db24-408-p.

Full text

Abstract:

Nearly 30% of patients with diabetes mellitus (DM) develop diabetic nephropathy over time. The long-term effect of weight loss, through lifestyle intervention, on kidney function remains unknown.We evaluated 94 patients with obesity and DM (12.8% type 1 DM and 87.2% type 2 DM, age 53.9±9.9 years, diabetes duration 10.9±10.3 years, weight 108.0±18.8 kg, and BMI 38.1±5.0 kg/m2) who enrolled in a 12-week multidisciplinary intensive lifestyle intervention (ILI) conducted in real-world clinical practice. Patients were prospectively followed for over 15 years. At one year, we stratified participants according to their percentage weight loss into: group A, who maintained ≥7% weight loss (48.9%) and group B, who maintained <7% weight loss (51.1%). At 15 years, the full cohort maintained an average of 8.0±2.8 kg weight loss (10.1±19.6%, p<0.0001). Group A lost 12.8±4.1 kg (15.1±21.9%, p<0.0001) and group B lost 3.9±3.4 kg (5.5±17.6%, p=0.024). A1C did not change from baseline in group A, but increased in group B (0.6±0.5%, p=0.027). Systolic blood pressure did not change in both groups. Diastolic blood pressure decreased only in group A from 77±3 mmHg to 73±3 mmHg (p=0.03). LDL-cholesterol and HDL-cholesterol significantly improved in both groups, however, triglycerides significantly increased in both groups. Estimated glomerular filtration rate (eGFR) increased in group A from 79.5±12.5 to 92.5±15.3 mL/min/1.73 m2 (p=0.02) and in group B from 80.5±7.5 to 90.8±13.3 mL/min/1.73 m2 (p=0.02). There was no significant change in urinary albumin/creatinine ratio from baseline or serum creatinine in both groups.We conclude that 12 weeks of ILI have a sustained improvement of renal function for up to 15 years after intervention. This improvement is more pronounced in those who maintained ≥7% weight loss at one year. Disclosure T. Salah: None. M. Al-Badri: None. A. Barbar Askar: None. A. Khater: None. S.E. Dhaver: None. A. Mottalib: None. O. Hamdy: Research Support; Eli Lilly and Company, Novo Nordisk. Consultant; Abbott Nutrition. Stock/Shareholder; Healthimation. Research Support; Gilead Sciences, Inc. Advisory Panel; Nemaura Medical, Twin Health, L-Nutra Inc.

APA, Harvard, Vancouver, ISO, and other styles

37

AL-BADRI, MARWA, ABD ALMASIH BARBAR ASKAR, ABDELRAHMAN KHATER, TAREQ SALAH, SHILTON E. DHAVER, FATIMAH AL-ROOMI, ADHAM MOTTALIB, and OSAMA HAMDY. "14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists." Diabetes 73, Supplement_1 (June 14, 2024). http://dx.doi.org/10.2337/db24-14-pub.

Full text

Abstract:

Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) emerged as an important treatment option for type 2 diabetes (T2D) for their dual efficacy in improving glycemia and reducing body weight. However, they significantly reduce fat free mass (FFM), a surrogate for muscle mass, putting patients at a higher risk for sarcopenia and its sequelae. It is unknown whether structured intensive lifestyle intervention (sILI), that includes higher protein intake and strength exercises, can mitigate muscle mass loss with GLP-1RA use. We retrospectively evaluated 53 patients with T2D enrolled in a 12-week multidisciplinary sILI (mean age 58.17±11.3 years; 51% male; weight 104.3±19.7 kg; BMI 36.1±5.6 kg/m2, A1C 7.4±1.3%) and divided them into two groups: group 1, already taking GLP-1RA (n=32), and group 2, not on GLP-1RA (n=21). Both groups were instructed to follow a hypocaloric structured medical nutrition therapy plan with increased protein intake to 1-1.5 gm/kg of adjusted body weight. They were also instructed to exercise for 360 minutes/week with more emphasis on strength exercises. Body composition was analyzed by bioelectrical impedance. At 12 weeks, group 1 lost 7.4±4.5 kg (p<0.001) and group 2 lost 6.2±5.4 kg (p<0.001), and their A1C decreased by 0.84%±1.1% (p<0.001) and by 1%±1.06% (p<0.001) respectively, with no differences between groups over time. Group 1 had no change in FFM compared to baseline while group 2 lost 1.4±2.6 kg (p<0.05). There was no difference in FFM loss between groups over time (p=0.28). Our findings suggest that increasing protein intake and strength exercises, as part of sILI, may mitigate the deleterious effect of GLP-1RA on muscle mass in patients with T2D. These results support recommending an increase in protein intake and incorporation of strength exercises when GLP-1RA is prescribed for patients with T2D to minimize muscle mass loss. Further research is needed to validate these findings in a randomized prospective study. Disclosure M. Al-Badri: None. A. Barbar Askar: None. A. Khater: None. T. Salah: None. S.E. Dhaver: None. F. Al-Roomi: None. A. Mottalib: None. O. Hamdy: Research Support; Eli Lilly and Company, Novo Nordisk. Consultant; Abbott Nutrition. Stock/Shareholder; Healthimation. Research Support; Gilead Sciences, Inc. Advisory Panel; Nemaura Medical, Twin Health, L-Nutra Inc.

APA, Harvard, Vancouver, ISO, and other styles

38

"Corrigendum." Journal of Cutaneous Medicine and Surgery 19, no. 6 (September 28, 2015): 604. http://dx.doi.org/10.1177/1203475415610304.

Full text

Abstract:

Guenther LC, Barber K, Searles GE, Lynde CW, Janiszewski P, Ashkenas J, for the Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines. J Cutan Med Surg. 2015;19(3):205-215. Original DOI: 10.1177/1203475415588652 Barber K, Searles GE, Vender R, Teoh H, Ashkenas J, for the Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. J Cutan Med Surg. 2015;19(3):216-226. Original DOI: 10.1177/1203475415576465 Poulin Y, Lynde CW, Barber K, Vender R, Claveau J, Bourcier M, Ashkenas J, for the Canadian non-Melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. J Cutan Med Surg. 2015;19(3):227-238. Original DOI: 10.1177/1203475415583414 Zloty D, Guenther LC, Sapijaszko M, Barber K, Claveau J, Adamek T, Ashkenas J, for the Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma. J Cutan Med Surg. 2015;19(3):239-248. Original DOI: 10.1177/1203475415586664 Sapijaszko M, Zloty D, Bourcier M, Poulin Y, Janiszewski P, Ashkenas J, for the Canadian Non-melanoma Skin Cancer Guidelines Committee. J Cutan Med Surg. 2015;19(3):249-259. Original DOI: 10.1177/1203475415582318 In the above articles, the following disclaimer from the Canadian Dermatology Association should have been included: The Canadian Dermatology Association (CDA) recognizes the scientific merit of these guidelines. The CDA did not participate in their development or provide content.

APA, Harvard, Vancouver, ISO, and other styles

39

"ATI 304B7 P/M." Alloy Digest 64, no. 8 (August 1, 2015). http://dx.doi.org/10.31399/asm.ad.ss1222.

Full text

Abstract:

Abstract ATI 304B7 P/M is a borated austenitic stainless steel of the type 304 base. Boron addition is accomplished through powder metallurgy. The uniform, fine dispersion of boron containing particles resulting from the P/M process imparts superior neutron absorption and enhanced toughness and ductility. This datasheet provides information on composition, physical properties, elasticity, and bend strength. It also includes information on corrosion resistance as well as forming, heat treating, joining, and powder metal forms. Filing Code: SS-1222. Producer or source: Allegheny Technologies Company.

APA, Harvard, Vancouver, ISO, and other styles

40

MATHER, KIEREN J., ANDREA MARI, JING LI, TIM HEISE, J. HANS DE VRIES, SHWETA URVA, TAMER COSKUN, ZVONKO MILICEVIC, AXEL HAUPT, and MELISSA K. THOMAS. "714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-714-p.

Full text

Abstract:

Tirzepatide (TZP) , a novel GIP-GLP-1 dual agonist, improved fasting measures of insulin sensitivity partially attributable to weight loss in Phase 2 studies. Studies in mice demonstrated that GIP receptor agonism with TZP improved insulin sensitivity independent of weight loss. To further evaluate insulin-sensitizing actions of TZP, we measured insulin sensitivity with hyperinsulinemic euglycemic clamps (M-value) in a 28-week double-blind randomized controlled trial comparing effects of TZP 15mg with placebo or semaglutide 1mg (SEMA) , a selective GLP-1RA, all subcutaneous QW. Linear regression was used to compare relationships of change in M-value versus change in weight across treatment groups. Change in M-value was related to absolute change and % change in weight (Figure) . Slopes of linear relationships with absolute and % weight change differed between TZP and SEMA (absolute change: p=0.015; % change: p=0.03) . Larger negative slopes were observed for TZP compared with SEMA on change in M-value related to absolute change and to % change in weight. These results suggest that TZP may provide greater improvement in insulin sensitivity than a selective GLP-1RA per unit weight loss, most evident in subjects with greater weight loss. Disclosure K.J.Mather: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.K.Thomas: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. A.Mari: Consultant; Lilly, Research Support; Lilly. J.Li: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. T.Heise: Advisory Panel; Novo Nordisk A/S, Research Support; ADOCIA, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Genova, Nestlé, Neuraly Inc., Novo Nordisk A/S, Sanofi, Zealand Pharma A/S, Speaker's Bureau; Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk A/S. J.De vries: Advisory Panel; ADOCIA, Novo Nordisk A/S, Zealand Pharma A/S, Speaker's Bureau; Novo Nordisk A/S. S.Urva: Employee; Eli Lilly and Company. T.Coskun: Employee; Eli Lilly and Company. Z.Milicevic: Employee; Eli Lilly and Company. A.Haupt: Employee; Lilly, Stock/Shareholder; Lilly. Funding Eli Lilly and Company

APA, Harvard, Vancouver, ISO, and other styles

41

WIESE, RUSSELL, ANNE DIB, CLAUDIA NICOLAY, SHERYL ALLEN, and CLARE LEE. "798-P: Shift to a Lower BMI Category Is Associated with Improved Cardiometabolic Measures in Adults with T2D Treated with Tirzepatide." Diabetes 72, Supplement_1 (June 20, 2023). http://dx.doi.org/10.2337/db23-798-p.

Full text

Abstract:

In the Phase 3 SURPASS studies of adults with T2D, the GIP/GLP-1 receptor agonist tirzepatide (TZP) provided clinically meaningful reductions in HbA1c levels and body weight. In this post-hoc analysis of TZP-treated participants in SURPASS 1-5 studies, we assessed whether those shifting to a lower BMI category would improve in cardiometabolic measures such as HbA1c, waist circumference (WC), systolic blood pressure (SBP), and lipid profiles. Changes in BMI category (<25 kg/m², 25- <30 kg/m², 30- <35 kg/m², 35- <40 kg/m², ≥40 kg/m²) from baseline to endpoint were assessed by study (N=3559), regardless of dose. BMI category shifts were grouped into “Improved” (shift to a lower BMI category, by at least one category), or “Stable/Worse” (no change/shift to a higher BMI category). At baseline, participants averaged 58 years, 93.36 kg, 53.6% were male, and 79.5% were white. While improvements in cardiometabolic measures were observed in both subsets of participants, numerically greater improvements in HbA1c, WC, SBP and lipid profile were observed for the 59% who improved their BMI category (Table 1). In the SURPASS studies, shifting to a lower and improved BMI category compared to a stable or worse BMI category was associated with greater improvement in cardiometabolic measures including HbA1c, WC, SBP, and lipid profile. Disclosure R.Wiese: Employee; Eli Lilly and Company. A.Dib: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. C.Nicolay: Employee; Eli Lilly and Company. S.Allen: None. C.Lee: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. Funding Eli Lilly and Company

APA, Harvard, Vancouver, ISO, and other styles

42

Gillette, Steve. "M ARKET D EVELOPMENT OF M ICROTURBINE C OMBINED HEAT AND P OWER APPLICATIONS." Distributed Generation & Alternative Energy Journal, March 18, 2004, 46–59. http://dx.doi.org/10.13052/dgaej2156-3306.1922.

Full text

Abstract:

Microturbines are gaining market acceptance through continuedproduct development, market education, government incentives, and animproved regulatory environment. This article describes the economicfactors driving customer acceptance of microturbine CHP solutions, il-lustrates several applications, and provides information regarding theregulatory situation in California. The examples sited in this article arefrom the author’s company, Capstone, but are intended to reflect thepotential application of similar microturbine products.

APA, Harvard, Vancouver, ISO, and other styles

43

GUERCI, BRUNO, FRANCESCO GIORGINO, KRISTINA BOYE, MARTIN FUECHTENBUSCH, ELKE HEITMANN, JEREMIE LEBREC, ANNE DIB, MARCO ORSINI FEDERICI, MARIA YU, and LUIS-EMILIO GARCIA-PEREZ. "726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-726-p.

Full text

Abstract:

TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in France, Germany, and Italy. Secondary objectives included assessments of HbA1c, body weight and treatment patterns. Clinical characteristics of the DU and LIRA cohorts at 24 months are described in the Table. Most patients receiving DU (856/1,014) initiated treatment at 1.5 mg/week and, among 286 patients with a significant treatment change, 237 were still receiving 1.5 mg/week. In the LIRA cohort, most patients (809/991) initiated at the starting dose 0.6 mg/day and 45% increased dose to 1.2 mg/day by Day 90; however, 17% of patients were already receiving 1.8 mg/day by Day 90. At the first significant treatment change 285/448 patients in the LIRA cohort were receiving 1.2 mg/day. Insulin was initiated by 79 and 97 patients in the DU and LIRA cohorts, respectively. Both treatments showed clinically meaningful effectiveness on HbA1c and weight, maintained over the 24-month study period. Disclosure B. Guerci: Advisory Panel; Amgen Inc., Medtronic. Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. F. Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Lilly Diabetes, Sanofi. Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. K. Boye: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Fuechtenbusch: Advisory Panel; Berlin-Chemie AG. Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp. Speaker's Bureau; AstraZeneca, Novo Nordisk. E. Heitmann: None. J. Lebrec: Consultant; Eli Lilly and Company. A. Dib: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Orsini Federici: Employee; Eli Lilly and Company. M. Yu: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. L. Garcia-Perez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.

APA, Harvard, Vancouver, ISO, and other styles

44

GIORGINO, FRANCESCO, BRUNO GUERCI, LUIS-EMILIO GARCIA-PEREZ, MARTIN FUECHTENBUSCH, JEREMIE LEBREC, MARCO ORSINI FEDERICI, ANNE DIB, ELKE HEITMANN, MARIA YU, and KRISTINA BOYE. "746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-746-p.

Full text

Abstract:

TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in France, Germany, and Italy. Primary objective: to assess the time patients remained on their first GLP-1 RA without a significant treatment change due to treatment- or diabetes-related factors. Kaplan-Meier (KM) probability (95% CI) of no significant treatment change at 24 months was 0.71 (0.68-0.74) and 0.53 (0.49-0.56) in the DU and LIRA cohorts, respectively (Figure) . Two-hundred and eighty-six (28.2%) and 448 (45.2%) patients receiving DU and LIRA, respectively, had a significant treatment change. The main driver of treatment change in the DU and LIRA cohorts was intensification with an add-on therapy (insulin or OAD) and intensification with dose increase of GLP-1 RA, respectively. KM probability (95% CI) of GLP-1 RA persistence at 24 months was high in both cohorts: DU 0.82 (0.80-0.85) ; LIRA 0.75 (0.72-0.78) . In summary, the probabilities of no significant treatment change over 24 months were estimated as higher in the DU cohort than in the LIRA cohort in this non-comparative analysis, with good persistence in both cohorts. Disclosure F. Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Lilly Diabetes, Sanofi. Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. B. Guerci: Advisory Panel; Amgen Inc., Medtronic. Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. L. Garcia-Perez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Fuechtenbusch: Advisory Panel; Berlin-Chemie AG. Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp. Speaker's Bureau; AstraZeneca, Novo Nordisk. J. Lebrec: Consultant; Eli Lilly and Company. M. Orsini Federici: Employee; Eli Lilly and Company. A. Dib: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. E. Heitmann: None. M. Yu: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. K. Boye: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.

APA, Harvard, Vancouver, ISO, and other styles

45

OKAMURA, TAKURO, MASAHIDE HAMAGUCHI, HIDETO OKAMOTO, NOBUAKI OKUMURA, and MICHIAKI FUKUI. "1620-P: Royal Jelly Improved Dysbiosis and Glucose Intolerance in db/db Mice." Diabetes 72, Supplement_1 (June 20, 2023). http://dx.doi.org/10.2337/db23-1620-p.

Full text

Abstract:

In this study, we have investigated the mechanisms of improvement of glucose intolerance via changes in gut microbiota using db/db mice. Eight-week-old db/m and db/db mice were divided into 5 groups and housed for eight weeks (n=6 for each group): db/m group without RJ (db/m), db/db mice without RJ (db/db), db/db mice with 0.2% RJ (db/db + 0.2% RJ), db/db mice with 1% RJ (db/db + 1% P), db/db mice with 5% RJ (db/db + 5% RJ) (Figure A). Body weight of db/db mice was higher than that of db/db mice fed with RJ (Figure B). Moreover, glucose tolerance evaluated by iPGTT and ITT were improved by RJ (Figure C-F). Next, the expression of inflammation-related genes (Tnfa, Ifng) and nutrient transporter genes (Cd36, Sglt1, and Pept1) in small intestine were increased in db/db mice more than in db/m mice, nevertheless significantly decreased by RJ (Figure G-K). In the gut microbiota analyses by 16S rRNA sequencing, it was found that seven taxa, including Firmicutes, were overexpressed in db/db mice, while seven taxa including short-chain fatty acid-producing bacteria such as the family Ruminococcaceae, the genus Butyricioccus, and the genus Acetiviblio were overexpressed in db/db +5%RJ mice in the LEfSe algorithm (Figure L). In summary, it is suggested that RJ might altere the gut microbiota and contributed to the improvement of metabolic disorders by changing the expression of genes related to nutrient absorption in the small intestine. Disclosure T. Okamura: Research Support; Yamada Bee Company, Inc. M. Hamaguchi: Research Support; Yamada Bee Company, Inc. H. Okamoto: Employee; Yamada Bee Company, Inc. N. Okumura: Employee; Yamada bee company, Inc. M. Fukui: None.

APA, Harvard, Vancouver, ISO, and other styles

46

Hoang Thuy Bich Tram, Nguyen, and Tran Thi Thuy Linh. "Institutional Quality Matter and Vietnamese Corporate Debt Maturity." VNU Journal of Science: Economics and Business 33, no. 5E (December 25, 2017). http://dx.doi.org/10.25073/2588-1108/vnueab.4099.

Full text

Abstract:

This article studies whether firm-level and country-level factors affect to the corporation's debt maturity in case of Vietnam or not. The paper adopts the balance panel data of 267 listed companies on two trading board HOSE and HNX in the period from 2008 to 2015, estimated by FEM, REM, 2SLS and GMM method. To intrinsic factors, research results show that financial leverage and default risk control have high positive statistical significance with the debt maturity, but tangible assets are lower than those factors. In addition, growth opportunities and company quality have negative impacts to the debt maturity. To external factors, the results point out that economic growth, stock market development and governmental regulation's efficiency demonstrate the positive relationship to the debt maturity with fairly low correlation levels. In spite of that, inflation rate, financial development, the rule of law, corruption control and the rights of creditor factors have negative correlations to the debt maturity. Keywords Debt maturity, long-term debt ratio, GMM system, firm-level factors, country-level factors References [1] Barclay, M., Smith, C., Jr., “The maturity structure of corporate debt”, Journal of Finance, 50 (1995), 609-631. [2] Kirch, G., Terra, P.R.S., “Determinants of corporate debt maturity in SouthAmerica: Do institutional quality and financial development matter?”, Journal ofCorporate Finance, 18 (2012) 4, 980-993.[3] Cai, K., Fairchild, R., Guney, Y., “Debt maturity structure of Chinese companies”, Pacific Basin Finance Journal, 16 (2008), 268-297.[4] Deesomsak, R., Paudyal, K. & Pescetto, G., “Debt Maturity Structure and the 1997 Asian Financial Crisis”, Journal of Multinational Financial Management ,19(2009) 1, 26-42. [5] Goyal, V.K., Wang, W., “Debt maturity and asymmetric information: Evidence from default risk changes”, Journal of Financial and Quantitative Analysis, 48 (2013), 789-817.[6] Tesfaye T. Lemma, Minga Negash, “Debt Maturity Choice of a Firm: Evidence from African Countries”, Journal of Business and Policy Research, 7 (2012) 2, 60-92[7] Sérgio Costaa, Luis M. S. Laureanoa, Raul M. S. Laureanoa, “The debt maturity of Portuguese SMEs: The aftermath of the 2008 financial crisis”, Social and Behavioral Sciences, 150 (2014 ), 172-181.[8] Myers, S. C., “The Capital Structure Puzzle”, Journal of Finance, 39 (1984), 575-592.[9] Lucas, D., and R. L. McDonald, R. L., “Equity Issues and Stock Price Dynamics”, Journal of Finance, 45 (1990),1019-1043.[10] Flannery, M. J., “Asymmetric Information and Risky Debt Maturity Choice”, Journal of Finance, 41 (1986), 19-37.[11] Douglas W. Diamond, “Monitoring and Reputation: The Choice between Bank Loans and Directly Placed Debt”, The Journal of Political Economy, 99 (1991) 4, 689-721.[12] Morris, “On corporate debt maturity strategies”, Journal of Finance, 31 (1976) 1, 29-37.[13] Myers, S. C.,“Determinants of Corporate Borrowings”, The Journal of Finance, 5 (1977), 147-175.[14] Amir Barnea, Robert A. Haugen, Lemma W. Senbet, “A rationale for debt maturity structure and call provisions in the agency theoretic framework”, The Journal of Finance, 35 (1980) 5, 1223-1234.[15] Jensen M. and W. Meckling, “Theory of the Firm: Managerial Behavior, Agency Costs, and Capital Structure”, Journal of Financial Economics, 3 (1976), 305-360.[16] Douglass C. North, “Institutions”, Journal of Economic Perspectives, 5 (1990) 1, 97-112.[17] Meyer, K. E., “Institutions, transaction costs and entry mode choice in Eastern Europe”, Journal of International Business Studies, 32 (2001), 357-67.[18] Barclay, M.J., Marx, L.M., Smith, C.W., “The joint determination of leverage and maturity”, Journal of Corporate Finance, 9 (2003), 149-167.[19] Johnson, S.A., “Debt maturity and the effects of growth opportunities and liquidity risk on leverage”, Review of Financial Studies, 16 (2003), 209-236.[20] Antoniou, A., Guney, Y., Paudyal, K., “The determinants of debt maturity structure: Evidence from France, Germany and the UK”, European Financial Management, 12 (2006) 2, 161-194.[21] Lopez-Gracia, J., Mestre-Barbera, R., “Tax effect on Spanish SME optimum debt maturity structure”, Journal of Business Research, 64 (2011), 649-65.[22] Custódio, C., Ferreira, A., Laureano, L., “Why are US firms using more short-term debt?”, Journal of Financial Economics, 108 (2013) 1, 182-212.[23] El Ghoul, S., Guedhami, O., Pittman, J., Rizeanu, S., “Cross-country evidence on the importance of auditor choice to corporate debt maturity”, Contemporary Accounting Research (2014).[24] Belkhir, M., Ben-Nasr, H., Boubaker, S., “Labor protection and corporate debt maturity: International evidence”, UAE University working paper (2014).[25] Stephan, A., Talavera,O., Tsapin, A., “Corporate debt maturity choice in emerging financial markets”, Quarterly Review of Economics and Finance, 51 (2011), 141-151.[26] Bae, K. H., Goyal, V. K., “Creditor rights, enforcement, and bank loans”, The Journal of Finance, 64 (2009) 2, 823-860.[27] Gonzalez-Mendez, V.M., “Determinants of debt maturity structure across firm size”, Spanish Journal of Finance and Accounting, 17 (2013), 187-209.[28] Mark Hoven Stohs, David C. Mauer, “The Determinants of Corporate Debt Maturity Structure”, Journal of Business, 69 (1996) 3.[29] Scherr, F. C. and Hulburt, H. M., “The Debt Maturity Structure of Small Firms”, Financial Management, 1 (2001), 85-111.[30] Magri, S., “Debt maturity of Italian firms”, Journal of Money, Credit and Banking, 42 2010, 443-463.[31] Oman, C., Köksal, B., “Debt maturity across firm types: Evidence from a major developing economy”, Emerging Markets Review, 30 (2017), 169-199.[32] Awartani, B., Belkhir, M., Boubaker, S., Maghyereh, A., “Corporate debt maturity in the MENA region: Does institutional quality matter?”, International Review of Financial Analysis, 46 (2016), 309-325.[33] Antonios Antoniou, Yilmaz Guney, Krishna Paudyal, The Determinants of Debt Maturity Structure: Evidence from France, Germany and the UK, European Financial Management, 12 (2006) 2, 161-194.[34] Antoniou, A., Guney, Y., Paudyal, K., “The determinants of capital structure: Capital market-oriented versus bank-oriented institutions”, Journal of Financial and Quantitative Analysis, 43 (2008) 1, 59-92.[35] Fan, J. P., Titman, S., Twite, G., “An international comparison of capital structure and debt maturity choices”, Journal of Financial and Quantitative Analysis, 47 (2012) 1, 23.[36] Garcia-Teruel P, Martinez-Solano P., “Short-term debt in Spanish SMEs”, Int Small Bussiness Journal, 25 (2007), 579-602.[37] Giannetti, M., “Do better institutions mitigate agency problems? Evidence fromcorporate finance choices”, Journal of Financial and Quantitative Analysis, 38 (2003) 1, 185-212.[38] Diamond, W., “Presidential address, committing to commit: Short-term debtwhen enforcement is costly”, The Journal of Finance, 59 (2004) 4, 1447-1479.[39] Qian, J., Strahan, E., “How laws and institutions shape financial contracts: The case of bank loans”, The Journal of Finance, 62 (2007) 6, 2803-2834.[40] Aris, “Legal systems, capital structure, and debt maturity in developing countries”, Corp. Gov., 24 (2016), 130-144.[41] Cuneyt Orman, Bülent Köksal, “Debt Maturity across Firm Types: Evidence from a Major Developing Economy”, Emerging Markets Review, 30 (2016). [42] Zheng, X., El Ghoul, S., Guedhami, O., Kwok, C., “National culture and corporate debt maturity”, Journal of Banking & Finance, 36 (2012) 2, 468-488.[43] Jun Qian, Philip E. Strahan, “How Laws and Institutions Shape Financial Contracts: The Case of Bank Loans”, The Journal of Finance, 62 (2007) 6, 2803-2834.[44] Vig, V., “Access to collateral and corporate debt structure: Evidence from a natural experiment”, The Journal of Finance, 68 (2013) 3, 881-928.[45] Cho, S., El Ghoul, S., Guedhami, O., Suh, J., “Creditor rights and capital structure: Evidence from international data”, Journal of Corporate Finance, 25 (2014), 40-60.[46] Mark Hoven Stohs, David C Mauer, “The Determinants of Corporate Debt Maturity Structure”, The Journal of Business, 69 (1996) 3, 279-312. [47] Kane, A., A. J. Marcus, R. L. McDonald, “Debt Policy and the Rate of Return Premium to Leverage”, The Journal of Financial and Quantitative Analysis, 20 (1985) 4, 479-499.[48] E. I. Altman, “Corporate financial distress: A complete guide to predicting, avoiding, and dealing with bankruptcy”, New York: John Wiley & Sons, 1983. [49] Mackie-Mason, Jeffrey K., “Do Taxes Affect Corporate Financing Decisions?”, Journal of Finance, 45 (1990) 5, 1471-1493.[50] Djankov, S., C. McLiesh, and A. Shleifer, “Private credit in 129 countries”, Journal of Financial Economics, 84 (2007), 299-329.

APA, Harvard, Vancouver, ISO, and other styles

47

PACZKOWSKI, ROSIRENE, MEREDITH HOOG, JENNIFER PELESHOK, MARIA YU, AHONG HUANG, BRENDAN LIMONE, and JANNA MANJELIEVSKAIA. "92-LB: Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with U.S. Real-World Data." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-92-lb.

Full text

Abstract:

A retrospective, observational analysis of administrative claims data from the IBM MarketScan Databases assessed adherence and persistence among GLP-1 RA naive adult patients with T2D newly initiating dulaglutide (DU) or oral semaglutide (OS) between Sept 2019 and Nov 2020. Patients had continuous enrollment in the 6-mo pre-index period and 6-mo follow-up periods. The DU patients were propensity-score matched 1:1 to OS patients (6,166 pairs) . The median age was 54 years at index date, and 48% were female. At pre-index, mean aDCSI was 0.6 and 10% of patients had ASCVD. Most patients used oral anti-hyperglycemic medication (87%) ; a smaller proportion used insulin (15%) . The most common prescribing provider was primary care (62%) . More DU patients were adherent (proportion days covered [PDC] ≥80%) (65% vs. 50%, p<0.001) and had higher mean PDC vs. OS (0.78 vs. 0.68, p<0.001) . More DU patients were persistent on therapy compared to OS patients (72% vs. 57% p<0.001) and had longer mean duration of persistence (148 vs. 128, p<0.001) . Among patients with ≥2 fills of their index drug, 73% of DU and 62% of OS patients were adherent. During the 6-mo follow-up period, DU patients had significantly higher adherence and persistence compared to OS patients. Disclosure R. Paczkowski: Employee; Eli Lilly and Company. M. Hoog: Employee; Eli Lilly and Company, Stock/Shareholder; Abbott, Eli Lilly and Company. J. Peleshok: Employee; Eli Lilly and Company, Eli Lilly and Company. M. Yu: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. A. Huang: None. B. Limone: None. J. Manjelievskaia: Employee; IBM Watson Health, Other Relationship; Eli Lilly and Company. Funding Eli Lilly and Company

APA, Harvard, Vancouver, ISO, and other styles

48

"Death of the Society's Company Secretary and Membership Secretary M. P. J. Garvey FCA." Mariner's Mirror 98, no. 2 (January 2012): 133. http://dx.doi.org/10.1080/00253359.2012.10708986.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

MARI, ANDREA, JING LI, SHWETA URVA, TIM HEISE, J. HANS DE VRIES, EDWARD J. PRATT, ROBERT J. HEINE, MELISSA K. THOMAS, ZVONKO MILICEVIC, and KIEREN J. MATHER. "722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-722-p.

Full text

Abstract:

We investigated the effect of tirzepatide (TZP) 15 mg (novel GIP-GLP-1 dual receptor agonist) , placebo and semaglutide 1 mg (SEMA) on beta-cell function using euglycaemic and hyperglycemic glucose clamps (EGC, HGC) and Mixed Meal Tolerance Tests (MMTT) in a 28-week double-blind randomized controlled trial of people with type 2 diabetes. During EGC and HGC, TZP improved insulin sensitivity (M-value) , first and second phase insulin secretion (ISR) and beta-cell glucose sensitivity (ratio of ISR and glucose increments) more than SEMA and placebo (Table; EASD symposium 2021) . During MMTT, both fasting and AUC glucose were reduced more with TZP than with SEMA or placebo, while incremental glucose AUC was reduced with TZP and SEMA vs. placebo similarly. Despite similarly reduced incremental glucose AUC, insulin AUC and incremental insulin AUC were reduced by TZP but not by SEMA. Model-derived beta-cell glucose sensitivity was increased with TZP and SEMA from baseline similarly. In contrast, ISR at 7.2 mmol/L glucose increased more with TZP than with placebo and SEMA (Table) . The glucose-lowering effect of TZP is mediated through improvements in multiple aspects of beta-cell function, including beta-cell glucose sensitivity and ISR, and in insulin sensitivity, resulting in pronounced lowering of fasting and postprandial glucose. These effects help explain the superior improvement in glucose control seen with TZP vs. comparators in clinical trials. Disclosure A. Mari: Consultant; Lilly. Research Support; Lilly. J. Li: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. S. Urva: Employee; Eli Lilly and Company. T. Heise: Advisory Panel; Novo Nordisk A/S. Research Support; ADOCIA, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Genova, Nestlé, Neuraly Inc., Novo Nordisk A/S, Sanofi, Zealand Pharma A/S. Speaker's Bureau; Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk A/S. J. De Vries: Advisory Panel; ADOCIA, Novo Nordisk A/S, Zealand Pharma A/S. Speaker's Bureau; Novo Nordisk A/S. E.J. Pratt: Employee; Eli Lilly and Company. R.J. Heine: Employee; Eli Lilly and Company. M.K. Thomas: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Z. Milicevic: Employee; Eli Lilly and Company. K.J. Mather: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Funding Eli Lilly and Company

APA, Harvard, Vancouver, ISO, and other styles

50

GIMENEZ, MARGA, KAMLESH KHUNTI, KRISTEN SYRING, LEVENIA A. BAKER, SURESH CHENJI, REBECCA J. THRELKELD, YU YAN, and MUNEHIDE MATSUHISA. "375-P: Indirect Treatment Comparison (ITC) of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia: Baqsimi, Gvoke, and Zegalogue." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-375-p.

Full text

Abstract:

Objective: To evaluate and compare the efficacy and safety of 3 ready-to-use glucagon treatments for severe hypoglycemia in adults and children with diabetes: Baqsimi (nasal glucagon) , Gvoke (glucagon injection) , and Zegalogue (dasiglucagon injection) . Methods: A systematic literature review was conducted to identify randomized clinical trials assessing the efficacy and safety of ready-to-use glucagon vs. reconstituted injectable glucagon. Bayesian fixed-effect network meta-analysis was used to perform the ITC of Gvoke and Zegalogue vs. Baqsimi. Endpoints included the proportion of participants achieving treatment success, maximum blood glucose, and treatment-emergent adverse events. Mean time to treatment success and to maximum blood glucose were also analyzed for Gvoke vs. Baqsimi, but not for Zegalogue due to reporting differences (mean vs. median) . Results and Conclusion: Ten trials were included in the ITC, including 4 for Baqsimi, 3 for Gvoke, and 3 for Zegalogue. Baqsimi had comparable efficacy with Gvoke and with Zegalogue (Table) , and all 3 treatments achieved high treatment success (>98%) in adults and children with diabetes. In adults, results from the combined T1D and T2D analysis were consistent with the T1D analysis, except a statistically significant faster time achieving treatment success observed for Baqsimi vs. Gvoke in the combined analysis. Disclosure M. Gimenez: Advisory Panel; Eli Lilly and Company, Medtronic, Novo Nordisk, Sanofi. Speaker's Bureau; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi. K. Khunti: Consultant; Abbott, Amgen Inc., AstraZeneca, Bayer AG, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, Lilly, Merck Sharp & Dohme Corp., Napp Pharmaceuticals Limited, Novartis AG, Novo Nordisk, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Servier Laboratories. Research Support; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi-Aventis Deutschland GmbH. K. Syring: Employee; Eli Lilly and Company. L.A. Baker: None. R.J. Threlkeld: Employee; Lilly Diabetes. Y. Yan: Employee; Eli Lilly and Company. M. Matsuhisa: Research Support; Nissui, Sysmex Corp. Speaker's Bureau; Astellas Pharma Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk, Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. Funding Funded by Eli Lilly and Company.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'P.M. Barber and Company'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles